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Abstract
Transactive response DNA binding protein, 43 kDa (TDP-43) is 416-residue RNA
processing and transport protein, observed in insoluble cytoplasmic aggregates
within affected neurons in neurodegenerative diseases.

TDP-43 has three

domains: the N-terminal (N), RNA-binding (R) and unstructured C-terminal
domains (G).

Unstructured domains often form intramolecular interactions

regulating other domains; our goal was to determine if such an interaction occurs
in TDP-43. In Far Western blots, tagged NR was observed to bind to G. A ten
residue C-terminal truncation of G virtually abolished binding and introduction of
phosphomimetics at Ser409/Ser410 also reduced binding. Sedimentation velocity
ultracentrifugation with tagged NR and G also revealed interaction, observed by a
shift in sedimentation coefficients when compared to those of the individual
polypeptides.

In vivo colocalization studies confirmed a cellular interaction

between fluorescently labeled NR and G.

This interaction has potential

implications for the regulation of TDP-43 and the mechanism of generation of
aggregative forms.

Keywords: TDP-43, intrinsically disordered protein, analytical ultracentrifugation,
protein interactions, Far Western blot, amyotrophic lateral sclerosis
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Chapter 1: Introduction
In devastating neurodegenerative diseases including amyotrophic lateral
sclerosis (ALS) and frontotemporal dementia (FTD), transactive response DNA
binding protein 43 kDa (TDP-43) has been identified as a hallmark component of
pathological intracellular inclusions found in patients (1–3). These TDP-43 positive
inclusions are typically found in both upper and lower motor neurons in the spinal
cord, cortex and hippocampus of affected individuals (4–6). Initially discovered as
bound to transactive response sequences in HIV DNA (7), TDP-43 has since been
implicated in multiple other diseases including cystic fibrosis (8, 9), Alzheimer’s
disease (10, 11), Parkinson’s disease (10) and Alexander’s disease (12).
Incomplete characterization of the structure and function of TDP-43 has thus far
prevented a thorough understanding of its roles in healthy and disease states.
TDP-43 is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP)
family of proteins (7).

hnRNPs have a characteristic RNA-binding domain,

comprised of highly structured nucleotide binding motifs called RNA recognition
motifs (RRMs), followed by an unstructured, glycine-rich C-terminal domain (8, 13–
15). The domain organization of TDP-43 is closely related to that of the hnRNP
A/B type, as demonstrated in the sequence alignment in Figure 1A&B (14, 15). In
addition to the RNA-binding and unstructured domains, TDP-43 has a structured
domain N-terminal to the RNA-binding domain, called the N-terminal domain, as
outlined in Figure 1A.
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Figure 1. Sequence illustration of the hnRNP family. A) Schematic diagram of
TDP-43 domain boundaries. Each domain is highlighted and named. The colours
will be carried throughout this work to represent each domain in further diagrams.
NLS-Nuclear

localization

signal;

NES-Nuclear

export

signal;

RRM-RNA

recognition motif. B) Sequence alignment of two hnRNPs, A1 and A2/B1, and the
414 residue TDP-43. The two RRM domains are highlighted in dark and light
green. The glycine residues are coloured blue.
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The human TARDBP gene is located on chromosome 1 at 1p36.21 and
contains 6 exons that can be alternatively spliced, encoding at least five TDP-43
variants in human cells (13). Orthologous TDP-43 genes have been identified in
other eukaryotes including mouse, Caenorhabditis elegans (C. elegans) and
Drosophila melanogaster (13). Human TDP-43 has high sequence identity with its
orthologous proteins in Drosophila (59%) and C. elegans (38%) (16). The greatest
sequence variation in orthologous TDP-43 proteins is in the C-terminal domain
which may cause variation in the functions of TDP-43 across species such as
RNA-binding but this is still not well understood (13). The most commonly reported
isoform of TDP-43 is 414 amino acids in length and it is recorded as isoform 1 by
the UniProt database (17). A second isoform of 416 amino acids was the primary
species isolated from healthy human brain (18) by this lab and it is the variant used
throughout this work.
TDP-43 is a primarily nuclear protein and is involved in many aspects of
RNA processing including transcription, stability, splicing and transport. Through
both nuclear export (NES) and localization signals (NLS) (Figure 1A), TDP-43
moves between the nucleus and the cytoplasm (19). The RNA-binding domain of
TDP-43 binds (UG)n-rich sequences in its target mRNA species; these sequences
are most commonly located in the 3’UTR or at splicing junctions (8, 20). Similar to
other hnRNPs, the C-terminal domain of TDP-43 has been demonstrated to bind
with many other proteins and has multiple sites for post-translational modification
(21). The C-terminal domain is intrinsically disordered and may also modulate
function through intramolecular interactions. Many studies have revealed the
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intrinsic aggregative properties of TDP-43 through both in vitro and in vivo methods
that replicate the TDP-43 positive inclusions found in neurodegenerative diseases
(22–28). These inclusions contain hyperphosphorylated and polyubiquitinated,
full-length and C-terminal fragments of TDP-43, as well as RNA species and
proteins found in stress granules (19).
Whether some degree of self-interaction/aggregation is functional or strictly
pathological is not known.

If self-interaction is not functionally relevant, then

pathological conditions may arise from natural protein aggregation due to excess
protein in the cell and the aggregation prone nature of the C-terminal domain.
However, if self-interaction is functional for increasing RNA stability or transport,
then it would have to be tightly regulated to avoid excessive interactions which may
lead to aggregation.

Developing a more basic understanding of TDP-43 is

necessary for understanding how TDP-43 correctly forms protein interactions and
whether mutations or modifications to TDP-43 that are associated with diseaserelated aggregation alter this process. Our overall hypothesis is that the domains
of TDP-43 do participate in intramolecular interactions.

1.1 Cellular Functions of TDP-43
TDP-43 was initially described as repressing the expression of HIV genes
through binding the TAR DNA sequence and blocking the transcription factors that
would initiate expression of HIV-1 genes (7). Since then, TDP-43 has been shown
to be associated with splicing regulation, mRNA stability, transcriptional regulation,
microRNA processing and the cellular stress response (Figure 2) (reviewed in 29).
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When TDP-43 becomes aggregated in disease states, it is plausible to assume
that normal function is reduced or lost. Gaining further understanding of the normal
functions of TDP-43 is critical to discovering the cellular basis of TDP-43
aggregation that leads to toxicity because very little is known about the regulation
of cell localization or of protein interactions in a functionally normal state.

1.1.1 TDP-43 localization—In a global analysis of the TDP-43 interactome, two
protein networks were strongly represented in the interactions with TDP-43:
Nuclear/transcriptional proteins and cytoplasmic/translational proteins (30). In the
first group, interacting proteins include transcription factors, hnRNPs, splicing
factors and RNA transport proteins. This does not come as a surprise since TDP43 has already been observed to play a critical role in many of these nuclear RNA
processes, and the experimental protocol lacked ribonuclease. The discovery of
interactions with the cytoplasmic translation machinery and ribosomal subunits
suggests TDP-43 stays associated with its target mRNA and continues to have a
role outside the nucleus (30). With roles in different compartments of the cell, the
NLS and NES within TDP-43 are necessary for TDP-43 distribution within the cell
(31). Perturbing either of these signals by mutations causes TDP-43 to aggregate
in the nucleus or cytoplasm of primary neurons, sequestering endogenous TDP43 with it (31). If mutations to the localization signals can have such a strong effect
on TDP-43, control over cellular location must be critical to its physiological
function.
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Figure 2. Schematic diagram of the various functions of TDP-43 within a cell. TDP43 is primarily found within the nucleus (shaded area), where it participates in
many functions in mRNA processing including mRNA stability, splicing and miRNA
processing. TDP-43 can also be transported from the nucleus to the cytoplasm
where it is involved in further processes including miRNA processing and mRNA
translation. TDP-43 is also a component of stress granules. After its cytoplasmic
function is complete, TDP-43 can then be transported back into the nucleus.
Shapes not corresponding to TDP-43 are protein placeholders to illustrate the
functions described by this figure. The functions illustrated include the hypothesis
of this thesis.
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1.1.2 Splicing—A well-characterized function of TDP-43 is its effect on splicing of
the cystic fibrosis transmembrane conductance regulator (CFTR) mRNA (8). This
is mediated by TDP-43 binding to a UG repeat rich region at the intron 8/exon 9
junction of the CFTR gene, where TDP-43 binding inhibits splicing. When TDP-43
binds at a junction, the spliceosome is blocked from acting on this junction and
skips to the next intron, effectively removing exon 9 and producing a non-functional
CFTR protein (8). Deletion of the TDP-43 C-terminal domain prevented both
human and Drosophila TDP-43 from properly interacting with, and splicing, the
target CFTR mRNA (13). C. elegans TDP-43 does not have the same disordered
C-terminal domain and also does not participate in splicing (13). Therefore, the Cterminal domain of TDP-43 is likely important for interaction with the splicing
machinery (8, 13). TDP-43 has also been found to have an effect on splicing of
mRNA for other genes including BRCA1, ETF1 and RXRG (32). The ability of
TDP-43 to interact with hnRNPs and other nuclear factors is required for proper
splicing function (33, 34).

Disruption of interactions, including induction of

cytoplasmic aggregates, removes the functional pool of nuclear TDP-43 and
reduces the ability of TDP-43 to aid in splicing (35).

1.1.3 mRNA stability—Along with splicing, TDP-43 has a role in mRNA stability.
Human neurofilament (hNEFL) mRNA was co-immunoprecipitated with TDP-43
(18). The binding region was mapped to the 3’UTR of hNEFL, where proper folding
of the mRNA creates a (UG)6 sequence for TDP-43 to bind (36). Binding and
stabilization by TDP-43 is necessary for proper hNEFL expression through
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interaction with other cellular RNA processing machinery (18). TDP-43 also binds
with HDAC6 mRNA and is necessary for maintaining HDAC6 mRNA and protein
levels in vivo (37). Knockdown of TDP-43 decreased the amount of HDAC6 in
HEK293 and SH-SY5Y cells and in Drosophila (37). Knockdown of TDP-43 also
induced instability of Atg7 mRNA, which is the transcript for a protein critical to
autophagy (38). If autophagy is compromised, aggregates of TDP-43 would not
be efficiently cleared from cells, inducing further toxicity (38). Conversely, TDP-43
knockdown increased the mRNA and protein levels of Cdk6 (39). CDK6 mRNA,
like hNEFL mRNA, has TDP-43 recognition sequences in the 3’UTR but the
opposite effect of TDP-43 expression on Cdk6 protein expression indicated a more
complicated role for TDP-43.

Perhaps the most important known mRNA

interaction of TDP-43 is with the TARDBP transcript itself; TDP-43 negatively
regulates its own expression by binding a recognition sequence in the 3’UTR and
destabilizing the TARDBP mRNA (40). This negative feedback loop suggests the
importance of closely regulating TDP-43 levels so that upon TDP-43 binding with
a mRNA substrate, the subsequent actions are correct for the fate of the bound
mRNA species.

1.1.4 microRNA processing—In a TDP-43 knockdown model in Hep-3B cells,
many miRNAs were discovered to be significantly decreased (41).

TDP-43

interaction with the Drosha and Dicer complexes is critical in miRNA biogenesis
(42). Immunoprecipitation with a FLAG antibody (anti-FLAG) pulled down a FLAGtagged Drosha and its complex where a direct interaction between Drosha and
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TDP-43 was observed, regardless of the presence of RNA, through TDP-43’s Cterminal domain (42). A similar direct interaction was found for cytoplasmic TDP43 and FLAG-Dicer (42). In the reciprocal experiment, anti-FLAG pulled down
FLAG-TDP-43 with Drosha or Dicer (42).

Deletion of the C-terminal domain

prevented interaction with the splicing machinery (42).

When TDP-43 was

knocked down in Neuro2A cells, miRNA production critical for neurite outgrowth
was reduced (42).

1.1.5 Cellular stress response—Another area of increasing interest is a role for
TDP-43 in the cellular stress response (43, 44).

After exposure to various

stressors including sodium arsenite, thapsigargin and heat shock, TDP-43 and
hnRNP A2 were sequestered to stress granules (44). In TDP-43 depleted cells,
stress granules took longer to form and were smaller in size (44). In addition to
granule formation, loss of TDP-43 also reduced expression of the key stress
response proteins, TIA-1 and G3BP (44). When the C-terminal domain of TDP-43
was deleted, stress granules failed to form after exposure to sorbitol (43). Another
study has shown that the family of FOXO transcription factors are activated by
TDP-43 after exposure to stress (45). The stress response triggers translocation
of TDP-43 to the cytoplasm, where it relieves inhibition of FOXOs by 14-3-3. TDP43 competitively interacted with 14-3-3, which allowed the FOXO proteins to return
to the nucleus and as a result expression of stress response proteins occurred
(45).

TDP-43 and 14-3-3 then associated with stress granules to sequester

unneeded mRNAs from translation (45). Additionally, TDP-43 may be involved in
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disrupting endoplasmic reticulum/mitochondria contacts through dissociation of
VAPB and PTPIP51, following activation of GSK-3β (46). Loss of the interaction
between VAPB and PTPIP51 causes an imbalance in Ca 2+ homeostasis and
activation of a stress response (46).

1.2 Domain Structure and Function
As previously stated, TDP-43 has three domains: the N-terminal, RNA-binding
and C-terminal domains. Figure 3 shows the amino acid sequence of TDP-43 and
highlights the important regions and residues for structure and function as currently
known.

1.2.1 N-terminal domain—The N-terminal domain (N) is classically defined as the
first 101 amino acids of TDP-43, and includes a putative NLS at position 82-98 (47,
48). The NLS is critical to TDP-43 function as while TDP-43 is primarily found in
the nucleus, it shuttles to and from the cytoplasm in response to cellular stress or
injury (47). Another interesting region within the N-terminal domain is a highly
conserved, highly acidic region (residues 9-23) but the exact function of this region
is

not

known

(8,

9).

Online

software

such

as

PredictProtein

(www.predictprotein.org) predicts the formation of β–sheets and α-helices within
the N-terminal domain of TDP-43 (49).
Recent nuclear magnetic resonance (NMR) and circular dichroism (CD)
studies on the N-terminal domain indicate the presence of secondary structures as
predicted (48, 50, 51). The NMR analysis on a polypeptide of TDP-43 residues 1-
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105 indicated the presence of a structured domain with some helices but the actual
structure formed could not be determined, as the workable concentration was too
low, however there was likely some presence of oligomers (50). CD analysis on
the same polypeptide indicated the presence of both β–strands and α-helices (50).
Similar studies on residues 1-102 of the N-terminal domain suggested the
existence of two conformations in equilibrium, a folded and an unfolded form, that
were not evident in a construct consisting only of residues 1-80 (51). The structure
was solved by NMR and the folded form was suggested to have a ubiquitin-like
fold (51).

The N-terminal domain also did not significantly contribute to

oligonucleotide binding (50).
Co-immunoprecipitation of differentially tagged TDP-43 proteins revealed
the ability of TDP-43 to form dimers, where the N-terminus was necessary for
dimerization (48, 52, 53). Further investigation through deletion mutants and in
vivo crosslinking showed the first 10 amino acids of the N-terminal domain to be
essential for dimer formation (48). In silico modeling also demonstrated that these
amino acids may form a loop structure that positions the rest of the TDP-43
molecule for correct interaction with another TDP-43 molecule (48).

1.2.2 RNA-binding domain—The RNA-binding domain (residues 102-262)
consists of two highly conserved RRMs: RRM1 and RRM2. The sequences are
highlighted in green in Figure 3 and the solution structure is shown in Figure 4.
RRMs are common in many well characterized nucleotide binding proteins,
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Figure 3. Amino acid sequence of the 416 residue TDP-43 isoform. Highlighted
are some important sequences and residues that are mentioned throughout this
work. The N-terminal domain (yellow) also contains the nuclear localization signal
(NLS) (pink). The RNA-binding domain (green) is made up of two RNA recognition
motifs (RRMs) in dark green, RRM1, and light green, RRM2. Within each RRM,
are two highly conserved ribonucleoprotein sequences (RNP-1 and RNP-2) that
contain the critical residues for RNA-binding (highlighted in green). The C-terminal
domain (blue) is glycine rich (highlighted in blue) and contains the hydrophobic
patch and the glutamine/asparagine rich (Gln/Asn-rich) region.
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including hnRNPs, Sxl and PABP (54). Structurally, RRMs fold with a 4-strand βsheet, connected by 3 α-helices Figure 4B (54). Tandem RRMs, as found in TDP43, typically increase the binding affinity of the protein to mRNA (54). RRM2 also
contains the putative NES (residues 239-250) (47). The two RRMs of TDP-43
appear to have different stabilities when exposed to denaturing conditions (55).
Structural studies using CD revealed an intermediate state in the melting of RRM2
that was not evident in the CD spectrum of RRM1 during chemical denaturation.
Most importantly, tethering the two RRMs with the natural linker sequence
increased stability compared to RRM1 alone (55). When RRM1 and RRM2 are
tethered, the hydrophobic residue clusters in RRM2 make contacts with RRM1,
contributing to stability (55). Disrupting the native structure of RRM2 by a cleavage
N-terminal to Arg208 increased the population of the intermediate state and this
mutant had a higher affinity for RNA than full RRM2 (55). It is unclear whether the
intermediate state is functionally relevant.
In 2009, the first crystal structure of TDP-43 was solved, with RRM2 only
(residues 192-265) in complex with ssDNA (56). Since then, the solution NMR
structure of the full RNA-binding domain, both RRM1 and RRM2 bound to an RNA
species (5’- GUGUGAAUGAAU-3’), was solved (Figure 4) (57). This new structure
was critical for gaining a better understanding of the RNA sequence specificity of
TDP-43. The RNA molecule was bound across the β-sheet surfaces of both RRMs
with the guanine in position 5 inserted between the two domains (Figure 4A). This
base made contacts with both RRMs, appearing to hold them in a rigid structure.
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Figure 4. Solution NMR structure of the RNA-binding domain (residues 96-267) of
TDP-43 (PDB: 4BS2). A) Full structure of this domain bound to an RNA species,
sequence 5’-GUGUGAAUGAAU-3’: RRM1 is displayed in darker green on the left,
bound with the 5’ end of the RNA, RRM2 is in light green. The NES is indicated
by the pink region within RRM2. B) A single RRM and the significant secondary
structures. The α-helices and β-sheets are colour coded in the corresponding
sequences at the bottom. C) Close up of RRM1 and the residues that make basespecific contacts with the RNA species: I107 and F149 (yellow). D) Close up of
RRM2 and the residues that make base-specific contacts with the RNA species:
F194 and F231 (yellow). This figure was constructed with Pymol.
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Only bases G1, G3, U4, G5, U8 and G9 made base-specific contacts with the
RRMs.

The 5’ nucleotide base bound with RRM1, while the downstream

nucleotides bound to RRM2; this is opposite to other proteins with tandem RRMs
where the 5’ base binds with the second RRM in the sequence (57).
Within each RRM of TDP-43, there are two conserved sequences called
ribonucleoprotein sequences (RNP-1 and RNP-2).

These have consensus

sequences of approximately eight residues that are hydrophobic or positively
charged to interact with nucleotides: KGFGFVRF for RNP-1 and LIVLGLPW for
RNP-2 (29, 58). RNP-1 and RNP-2 are located in the β-sheet, creating a binding
surface for ssDNA or RNA. Figure 4B and C highlights these residues and the
direct contacts made with an RNA oligo, as observed in the NMR structure. In
RRM1, Ile109 and Phe149 make direct contacts with bases U4 and G5,
respectively. In RRM2, Phe194 and Phe231 make contacts with U8 and G9,
respectively. These contacts appear like base-stacking interactions that precisely
position the RNA and likely contribute to specificity (57). Introducing the mutations
F147L and F149L to TDP-43 completely abolished binding with both (TG)6 and
(UG)6 species (20, 59).

Based on the NMR structure, the precise UG-rich

consensus sequence for binding to TDP-43 was suggested to be 5’GNGUGNNUGN-3’ (16,17).

Finally, RRM1 was crystallized alone with (TG)n

ssDNA (59). The ssDNA bound to the β-sheet surface with the same orientation
as observed in the NMR structure, where the nucleotides at G2, G4, C5 and G6
make direct contacts with the protein (59). This finding established a similar
consensus sequence for ssDNA binding as with RNA.
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Following the discovery of RRMs in TDP-43, oligonucleotide binding assays
were conducted to determine the binding specificity of TDP-43. TDP-43 is capable
of binding both (UG)n and (TG)n repeats in RNA and ssDNA, respectively (20, 56).
Binding was observed with sequences of 3-12 repeats, where affinity increased as
the oligonucleotide length increased. Using a truncated TDP-43 with only the
RNA-binding domain, the Kd of (UG)n binding decreased from increasing
oligonucleotide length from 3,060 nM (n=3) to 2.79 nM (n=8) (56). TDP-43 did not
efficiently bind with non-(UG)n sequences that were tested (56). Deletion of RRM1,
but not deletion of RRM2, abolished nucleotide binding and RRM1 alone bound
(UG)n/(TG)n repeats with a much higher affinity than RRM2 (20). Surprisingly,
RRM2 bound more strongly with smaller oligonucleotides than larger, opposite to
what was measured with RRM1 (56). In a crystal structure of RRM2 alone, dimers
were observed but it is not clear whether this dimerization interface is biologically
relevant or a crystal contact only (56). Crosslinking immunoprecipitation was used
to find the binding sequences within the 3’UTR of TARDBP mRNA for a construct
of the RNA-binding domain only (60). Of the two identified oligonucleotides, the
longer sequence bound with higher affinity than the shorter, Kd = 112 nM and 262
nM, respectively (60). In addition, comparable affinities were measured for a
similar construct with the residues Phe229 and Phe231 of RRM2 mutated to
leucines. The Phe residues of RRM2 were not as critical to RNA binding, unlike
the similar residues in RRM1 (60).
It appears that regions with a UG-rich sequence provide more favourable
binding conditions for TDP-43.

Protein binding is dynamic, therefore more
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available binding sequences allow for regulation by TDP-43 to be maintained for a
longer time (60). In addition, correct binding by RRM1 is most important for
sequence recognition where as RRM2 merely contributes to binding.

1.2.3 C-terminal domain—Perhaps the most interesting domain of TDP-43 is the
C-terminal domain, consisting of residues 263-414. This domain is glycine-rich
(25%) and predicted to be intrinsically disordered by the online structure prediction
software, DISOPRED (http://bioinf.cs.ucl.ac.uk/psipred/?disopred=1) (61, 62).
Figure 5 shows the output from DISOPRED, where a probability of 1 is indicative
of a likely region of disorder. The C-terminal domain, indicated by blue, is largely
disordered. The region of predicted order within the C-terminal domain has been
labelled a “hydrophobic patch” (residues 318-343; HP) and through solution NMR
studies of a peptide encompassing resides 311-360, was determined to form a
helix-turn-helix motif in solution (63). There is also a region rich in glutamine and
asparagine (residues 344-365; Q/N) that has been implicated in nucleating TDP43 aggregation (24, 64). These two regions are labelled in Figure 5.
The C-terminal domain has been observed as a key part of TDP-43 protein
interactions. TDP-43 was first observed to interact with hnRNP A1, hnRNP A2/B1
and hnRNP C1/C2, while deletion of the C-terminal domain ablated the interaction
(33). The region of interaction was more precisely mapped to residues 321-366
by truncating TDP-43 and measuring interaction with hnRNP A2 (65). Introducing
a synthetic peptide corresponding to this region was even capable of disrupting
TDP-43/hnRNP A2 interaction. This 45 residue region is highly conserved in
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Figure 5. Disorder prediction and sequence outline of TDP-43 structure. A) The
disorder prediction for the full TDP-43 sequence shows a high level of disorder
within the C-terminal domain (blue). Calculated using DISOPRED software. Two
regions of the C-terminal domain are indicated: the hydrophobic patch (HP),
residues 318-343, and the Gln/Asn-rich region (Q/N), residues 344-365.
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homologous TDP-43 proteins across species, demonstrating an importance for
interaction with hnRNPs (65). Upon closer inspection, the C-terminal domain has
a particularly glutamine/asparagine (Gln/Asn)–rich region (residues 344-365)
located within the protein interacting region (24). Polyglutamine or Gln/Asn-rich
regions are highly aggregation-prone and often nucleate toxic protein aggregates
(66).

C-terminal fragments of TDP-43 containing this region form insoluble

inclusions in cells and even sequester endogenous TDP-43 in cells (24). The
expression of 12 tandem repeats of residues 342-366 could form aggregates within
cells and these aggregates could sequester endogenous TDP-43 (64).
In addition to the Gln/Asn-rich region, the aforementioned “hydrophobic
patch” was also found to contribute to TDP-43 aggregation (63). A polypeptide of
TDP-43 residues 311-360, which contained the hydrophobic patch, appeared to
form some α-helical structure after analysis by CD and NMR spectroscopy (63).
After incubation, the percentage of α-helical structure decreased while the β-sheet
content increased, consistent with observations in other polyglutamine aggregate
proteins (63, 67). Deletion of the hydrophobic patch decreased the amount of
aggregation observed in cells (63). The combination of the hydrophobic patch and
the Gln/Asn-rich region was named the “amyloidogenic core” for its resemblance
to other β-amyloid aggregating proteins where α-helix to β-sheet structural
transformation propagates aggregation (63, 68).

1.2.4 TDP-43 interactions and aggregation—TDP-43 protein is found aggregated
in multiple diseases (2). The aggregates often contain C-terminal fragments of
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TDP-43, cleaved at Arg208, which is located in the first helix of RRM2 (2, 22).
Overexpression of this fragment in cells triggered aggregation similar to that found
in patient cases (22) while deletion of the C-terminal domain prevented it (69).
Over 40 TDP-43 mutations, the majority of which are in the C-terminal domain
(Figure 6), have been associated with disease (70). The different mutations had
varying effects on aggregation by stabilizing or destabilizing structures that were
considered relevant for aggregate formation (68).
While C-terminal mutations are not necessary for toxic inclusions to form, it
is clear that the C-terminal domain is critical for normal structure and function of
TDP-43. Its intrinsic tendency for protein interaction may lead to small oligomers
that are biologically normal and pathogenic aggregation may only be due to
dysregulation of this tendency. This is why a more basic understanding of the
normal functions of TDP-43 will be critical for understanding its role in disease.

1.3 TDP-43 in Disease Pathology
As previously mentioned, TDP-43 was first discovered bound to TAR
sequences of HIV-1 DNA, repressing transcription of these genes (7). Since then,
the active involvement of TDP-43 in preventing HIV-1 replication in immune cells
has been refuted (71) but evidence for TDP-43 involvement in the pathogenesis of
other diseases has arisen.
In cystic fibrosis (CF), TDP-43 binds at the 3’ splice site of exon 9 in CFTR
mRNA, excluding exon 9 from the mature mRNA. The resulting protein is nonfunctional (3, 57). This splice site has a (UG)m(U)n region in which polymorphisms
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Figure 6. Mutations in TDP-43 in neurodegenerative diseases. A) Highlights the
full sequence of TDP-43 where the identified mutations ( ) are largely concentrated
to the C-terminal domain. One mutation, D169G is in RRM1.

B) Mutations

currently associated with neurodegenerative diseases in the C-terminal domain
(70).
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introduce more or less favourable sites for regulatory factors to bind. Knockdown
of TDP-43 in culture and patient cells, with or without unfavourable sequences,
reduced the amount of misspliced CFTR. This finding suggests a critical role of
TDP-43 in the regulation of splicing and a possible therapeutic target for patients
with CF (72).
TDP-43 is also found in cellular inclusions in neurodegenerative diseases
such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)
(26, 53).

These cytoplasmic inclusions contain TDP-43 that is often hyper-

phosphorylated, ubiquitinated and N-terminally cleaved (1–3). TDP-43 cleavage,
similar to that observed in patients, was induced in vitro after exposure to caspase3 and caspase-7 (73, 74). There are three predicted cleavage sites within TDP43 for caspase cleavage at

10DEND, 86DETD, 216DVMD

with predicted cleavage

products of 42, 35 and 25 kDa, respectively (73). Two fragments, 25-kDa and 35kDa (73), of TDP-43 have been identified in patients with neurodegenerative
diseases and similar polypeptides were observed experimentally to recapitulate
the pathological aggregates observed in patients (26, 53).

Caspase-3 and

caspase-7 mediated cleavage was also induced in multiple cells lines including
HeLa (cervical cancer) and THP-1 (acute monocytic leukemia) after a treatment to
reduce the Ca2+ availability in vivo (74).
Further investigation into TDP-43 involvement in neurodegenerative
diseases revealed cleaved and phosphorylated TDP-43 inclusions in the brains of
Alzheimer’s patients who developed cognitive impairment and patients with Lewy
body dementia (11, 75). With over 40 TDP-43 mutations identified to date in
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patients with neurodegenerative disease (Figure 6) (76–78), it is becoming evident
that aggregation of TDP-43, and therefore a loss in critical RNA processing, has a
profound effect on neuronal homeostasis, leading to disease.

1.4 Post-Translational Modifications of TDP-43
A critical step in TDP-43-related pathology is thought to be aberrant
phosphorylation of multiple residues in the C-terminal domain including Ser379,
Ser403, Ser404, Ser409 and Ser410 (79). The exact sites of phosphorylation were
initially investigated through antibodies specific for phospho-epitopes of TDP-43.
The 5 sites were confirmed to be phosphorylated in inclusions found in the brains
of patients who were diagnosed with either ALS or FTD (79). Next, in vitro kinase
assays were used to determine that casein kinase 1 (CK1) was likely responsible
for phosphorylating TDP-43 and that aberrantly phosphorylated TDP-43 formed
SDS-insoluble oligomers (79).

Mass spectrometry confirmed the above 5

phosphorylated residues in recombinant TDP-43 treated with CK1, in addition to
24 other phosphorylated residues (80). This work involved in vitro incubation of
CK1

with

recombinant

TDP-43

and

therefore

non-biologically

relevant

phosphorylation could have occurred. The kinase CDC7 may also be involved in
phosphorylating TDP-43 (81).
Additional studies compared patient-derived inclusions with fresh rat brain
and found phosphorylated Ser409 (pSer409) and phosphorylated Ser410
(pSer410) in the patient samples only (82). In C. elegans models of ALS (TDP-43
bearing a G290A, A315T, or M337V mutation) pSer409/pSer410 was detected, as
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well as in the insoluble protein fraction of strains expressing wild-type TDP-43
(25).

A phosphomimetic TDP-43 with Ser409Glu/Ser410Glu expressed in

Neuro2A cells induced toxicity and cell death (83). These studies suggested that
phosphorylation of these residues was not a normal post-translational modification
of TDP-43.
There is currently no evidence of the level of in vivo phosphorylation in a
healthy cellular environment.

Without understanding this, it is difficult to

understand exactly what sites are pathological during formation of TDP-43
aggregates or when this aggregation occurs. One theory is that as a result of
disease

pathogenesis,

kinases

become

highly

active

and

abnormal

phosphorylation occurs thus leading to aggregation. In a neuroblastoma cell line,
aggregates containing phosphorylated C-terminal fragments of TDP-43 (residues
220-414) were more slowly cleared by the ubiquitin-proteasome system (UPS)
than unmodified fragments (84).
In an alternative theory, phosphorylation was proposed to occur after
aggregation as a possible mechanism to facilitate clearance of the aggregates. In
HEK293T and Neuro2A cells, C-terminal fragments (residues 252-414) formed
cytoplasmic aggregates that were phosphorylated at the expected five Ser
residues: 379, 403, 404, 409 and 410 (85, 86). The fragments were then mutated
to contain either Asp/Glu (phosphomimetic) or Ala at the 5 phosphorylation sites.
Fewer aggregates of the phosphomimetic C-terminal fragments were observed
than the Ala fragments (86). The reduction in aggregate formation suggested
phosphorylation occurs as a means of protection from larger aggregate formation
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(85, 86). In a time course assay, more phosphorylated aggregates were detected
at later than earlier time points (87, 88). However, phosphomimetics in full length
TDP-43 did not show a significant reduction in aggregation (86).
Finally, disruption of the UPS with an inhibitor also led to increased
phosphorylation and aggregate formation of mutant TDP-43 compared to cells with
a functional UPS (89), suggesting that impaired protein degradation may also
contribute to TDP-43 aggregation (88, 89).
Though there is significant conflicting information, it appears that
phosphorylation of TDP-43, at least at Ser409/Ser410, is not a normal event for
TDP-43 function. Elucidating the biochemical effect of phosphorylation would be
an important piece of information in understanding the transition of soluble TDP43 to aggregate.

1.5 Initial Evidence of Interactions
When work with TDP-43 began in the Dunn lab, it was observed that a GSTtagged, full-length TDP-43 protein (GST-NRG), expressed in Escherichia coli, was
insoluble and spun down in the pellets of both low and high speed centrifugations
(Figure 7A).

Much of the TDP-43 literature has described the intrinsically

disordered C-terminal domain as aggregation prone, suggesting this may be
contributing to the insolubility of the full length TDP-43. Two models of aggregation
were then considered for explaining the insolubility of full length TDP-43 as
demonstrated in Figure 7B. The first suggests the C-terminal domain of one TDP43 molecule interacting with the N-terminal or RNA-binding domain of another
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TDP-43. The free C-terminal domain then binds with another TDP-43, causing a
continually oligomerizing chain.

The second depends only on the intrinsic

aggregation of the C-terminal domain: many C-terminal domains interact, creating
many punctate aggregates. Of the two models, the first would be more easily
remedied by creating a split construct that would express the C-terminal domain
as a separate polypeptide from the rest of the tagged TDP-43 molecule. This was
achieved by inserting a ribosome re-initiation site (RRS) consisting of overlapping
translational termination and initiation codons between the RNA-binding domain
and C-terminal domain (Figure 7C). When this mRNA is expressed the ribosome
would translate the GST-NR polypeptide and terminate at the stop codon, but
remain bound to the mRNA due to the presence of a weak Shine-Delgarno site.
Translation would then begin again, synthesizing the G polypeptide in a theoretical
1:1 ratio to GST-NR (Figure 7D). After induction of this plasmid and the same
extraction conditions, the split in TDP-43 was observed to reduce the level of
insoluble protein and both polypeptides remained in the high speed supernatant
(Figure 7E). This dual expression allows for any interdomain interactions in TDP43 while preventing the large aggregate formation (Figure 7F).
With soluble protein, the next step was to purify the two TDP-43
polypeptides separately. To achieve this, a number of column chromatography
techniques were used, including ion exchange (DEAE-Sepharose; IX), to separate
the polypeptides based on their differing intrinsic properties. What was observed
was coelution of GST-NR and G, even after consecutive IX columns.
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Figure 7. Justification for construction of the split TDP-43 construct, GST-NR_G.
A) Coomassie stained gel showing the aggregated GST-TDP-43, located in the
pellets of cell lysates (red arrow). B) Two proposed models of aggregation of TDP43 (yellow: N-terminal domain; green: RRM domains; blue: C-terminal domain).
C) Schematic diagram of the split TDP-43 plasmid. D) Schematic of the two
polypeptides, GST-NR and G (bottom), created with the plasmid in C), compared
to full length GST-TDP-43 (top). E) Coomassie stained gel of the now soluble
GST-NR (top red arrow) and G (bottom red arrow) polypeptides. F) Model of how
GST-NR and G can interact without forming any large aggregates.
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Figure 8 shows the result of one such IX column, DEAE-Sepharose. Lanes 6-10
show GST-NR and G eluting in the same fractions through the applied NaCl
gradient, though G was not expected to interact with the column.

The two

polypeptides were confirmed by mass spectrometry using a concentrated fraction
from this analysis (Figure 8, Lane 16). This observation introduced an interesting
theory that intra- or intermolecular interactions may form between the two
polypeptides and the existence of such an interaction became the hypothesis of
this thesis work.

1.6 Intrinsically Disordered Protein Regions
Intrinsically disordered protein regions (IDPRs) do not form rigid secondary protein
structures, but rather form transient structures dictated by nearby binding partners
or environmental factors (22, 23). IDPRs in some proteins have autoinhibitory
functions through intramolecular interaction with a functional domain of the same
polypeptide and inhibit functions such as subcellular localization, ligand interaction
and enzymatic function (92, 93). Relieving inhibition may involve post-translational
modification (commonly phosphorylation), proteolysis or ligand binding (92, 93).
Known autoinhibited proteins include CaMKI, Src and moesin (93). For example,
the C-terminal domain of moesin is an IDPR which binds intramolecularly to its
FERM domain, inhibiting interactions with binding partners of moesin (93, 94).
While bound, the C-terminal domain adopts a helical secondary structure. After
phosphorylation of a threonine residue within this domain, it is thought that the
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Figure 8. Coelution of the GST-NR (58 kDa) and G (16 kDa) polypeptides,
indicated by the two red arrows. Lane 2 shows the sample loaded on the column.
Lane 3 is the flow-through proteins. Lanes 4-14 show the eluted proteins through
the NaCl gradient. Lane 16 shows the concentrated eluted protein run on a
separate gel, the bands indicated by arrows were analyzed by mass spectrometry.
The upper band was GST-NR and the lower band G.
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helical structure is destabilized, causing a loss of binding and therefore inhibition
(93, 94). We postulate that a similar interaction may exist in TDP-43.
Some models for intramolecular interaction of TDP-43 domains are shown
in Figure 9. The C-terminal domain may interact with either the N-terminal or RNAbinding domain of the same TDP-43 molecule, a region of another TDP-43
molecule or involve a mediator protein.

There is no current evidence for

autoinhibition by the C-terminal domain, but there are regions of the C-terminal
domain that participate in protein interactions and aggregation. As previously
discussed, the C-terminal domain also contains at least 2 serine residues, S409
and S410, that are confirmed to be phosphorylated in many patients with
neurodegenerative disease (21).

These phosphorylation events could be

evidence for autoinhibition because as previously mentioned, by means of
relieving inhibition is post-translational modification. However, the physiological
levels of phosphorylated TDP-43 and its functional role have yet to be determined.

32

Figure 9. Different proposed models of intra- and intermolecular interactions by the
TDP-43 C-terminal domain. A) The non-interacting form of TDP-43. The Nterminal domain is indicated in yellow, the RNA-binding domain is indicated in
green and the C-terminal domain in blue. B) The C-terminal domain folds and
makes many interactions with the N-terminal domain and RNA-binding domains.
C) Only a small region of the C-terminal domain is involved in interactions with the
RNA-binding domain. D) Only a small portion of the C-terminal domain is involved
in interactions with the N-terminal domain. E) The interaction is intermolecular and
involves two TDP-43 molecules. F) A potential mediator protein (indicated by red)
serves as an intermediary between the domains of TDP-43.
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1.7 Hypothesis
Developing a more thorough understanding of TDP-43 and its normal,
biological structure and function is necessary for finding the critical events leading
to disease onset. My hypothesis is that the C-terminal domain of TDP-43 is
involved in intra- or intermolecular interactions (Figure 10). To test this hypothesis
I will create constructs expressing specific regions of TDP-43 and subject them to
various biophysical and cell biology techniques to elucidate possible interdomain
interactions. The constructs will be studied in isolated conditions to reconstitute
interactions and to confirm the important binding region within the C-terminal
domain.
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Figure 10. Cartoon diagram of the predicted binding of TDP-43 domains. When
TDP-43 is in a monomeric “closed” state, the C-terminal domain (blue) forms an
intramolecular interaction with the N-terminal domain (yellow) or RNA-binding
domain (green). The dimeric “closed” state is included because its formation is
also possible since TDP-43 has been observed as a dimer. In the “open” state,
the intramolecular interaction has been relieved.

35

Chapter 2: Experimental Procedures
2.1 TDP-43 Construct Cloning
The TDP-43 coding construct used in this study was provided by Dr.
Kathryn Volkening. This was a neuronal variant of TDP-43, cloned from human
brain which encodes a 416 amino acid TDP-43 variant.

Its isolation and

expression was reported by Strong et al (2007) (18).
The proteins used in this study were all cloned into the parent plasmid,
pEBT7, which contains a T7 promoter, ampicillin resistance gene and an Nterminal TEV cleavable His6-Thioredoxin- (HT-) tag (95). Any plasmids were
isolated by alkaline lysis or QIAprep Miniprep extraction from MM294 or BL21DE3
E. coli cells. After restriction endonuclease (RE) digestion, all DNA fragments were
run on 0.8% agarose gels and purified by excision from the gel and repeated
freezing at -20°C and thawing. The final thawed sample was centrifuged in a
desktop centrifuge through fibre floss to extract the DNA. The plasmids pCB1,
pSD600, pSD639, pSD747, pSD748 and pSD749 were made by Yumin Bi and Dr.
Stan Dunn and were used throughout this work.
The plasmid pKD006 was made by ligating the 1257-bp BamHI/HindIII
fragment from pCB1 with the 1320-bp HindIII/PstI and 4495-bp PstI/BamHI.
fragments from pEBT7. pKD006 expressed full- length TDP-43 with an N-terminal
HT tag. The plasmid pKD004 was made by ligating the 790-bp BamHI/HindIII
fragment from pSD600 with the 1320-bp HindIII/PstI and 4495-bp PstI/BamHI
fragments from pEBT7.

pKD004 expressed the N-terminal and RNA-binding

domains with an N-terminal HT tag.
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Quickchange mutagenesis by PCR was used to create a number of
mutations to pSD639, which expressed the C-terminal domain with an N-terminal
HT tag. The reactions with the forward and reverse primers were carried out in
separate tubes and utilized the KOD Hot Start DNA polymerase (EMD Millipore
Corp). The thermocycler protocol started at 94°C for 5 min, then cycled [94°C for
40 s, 55°C for 40 s, 72°C for 5 min] 30 times. The forward and reverse reactions
were combined and returned to the thermocycler for annealing—95°C for 5 min,
90°C for 1 min, 80°C for 1 min, 70°C for 30 s, 60°C for 30 s, 50°C for 30 s, 40°C
for 30 s and 37°C hold. The DNA was then cleaned up with a PCR cleanup kit
(BioBasic Canada Inc., Markham ON) and DpnI-digested to degrade the template
DNA. Table 1 outlines the plasmids made by this method.
Further cloning by Quickchange mutagenesis was performed to construct a
set of plasmids that express truncated versions of the C-terminal domain variants.
Forward and reverse primers were designed to insert a second BamHI site within
the C-terminal domain gene sequence. PCR reactions were run and digested as
previously described. Purified plasmids were then digested with BamHI and the
5917-bp or 5878-bp fragment was ligated by itself, creating the truncated Cterminal fragment. Table 2 outlines the plasmids made by this method.
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Plasmid

Name

pKD011

HT-G-M337V

pKD012

HT-G-Δ407

Primers (5’ to 3’)
F:CAGTTGGGGTATGGTGGGCATGTTAGC
R:GCTAACATGCCCACCATACCCCAACTG
F:CTCAAGCATGGATTAAGTCTTCTGGCTG
R:CAGCCAGAAGACTTAATCCATGCTTGAG
F:CTCAAGCATGGATTCTAAGGAATCTGGCTGGGG

pKD013

HT-G-S409D

AATGAATC
R:GATTCATTCCCCAGCCAGATTCCTTAGAATCCAT
GCTTGAG
F:GCATGGATTCTAAGTCTGAAGGCTGGGGAATGA

pKD015

HT-G-S410D

ATCAC
R:GTGATTCATTCCCCAGCCTTCAGACTTAGAATCC
ATGC
F:GTTAGTGATTCATTCCCCAGCCkTCkTCCTTAGAA

pKD017

HT-G-SS409DD

TCCATGCTTGAGCCAAAGCCTCCATTAAAAC
R:GTTTTAATGGAGGCTTTGGCTCAAGCATGGATTC
TAAGGAkGAkGGCTGGGGAATGAATCACTAAC

pKD027

HT-G-ΔNH

pKD028α

HT-G-S409D-ΔNH

F:GGCTGGGGAATGTAACCTAGGAAGC
R:GCTTCCTAGGTTACATTCCCCAGCC
F:GGCTGGGGAATGTAACCTAGGAAGC
R:GCTTCCTAGGTTACATTCCCCAGCC

F-forward primer; R-reverse primer; k-G or C in sequence; α-parent plasmid was pKD013

Table 1. List of plasmids and primers constructed by Quickchange mutagenesis.
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Plasmid

Name

Parent
Plasmid

pKD019

HT-G386-416

pSD639

pKD020

HT-G399-416

pSD639

pKD021

HT-G386-406

pKD012

pKD022

HT-G399-406

pKD012

pKD023

HT-G386-416S409D

pKD013

pKD024

HT-G399-416S409D

pKD013

pKD025

HT-G386-416DD

pKD017

pKD026

HT-G399-416DD

pKD017

Primers (5’ to 3’)
F:CAATTGGTTGGGGATCCGCATCCAA
TGCAGGG
R:CCCTGCATTGGATGCGGATCCCCAA
CCAATTG
F:CAGTGGTTTTAATGGATCCTTTGGCT
CAAGCATGG
R:CCATGCTTGAGCCAAAGGATCCATT
AAAACCACTG
F:CAATTGGTTGGGGATCCGCATCCAA
TGCAGGG
R:CCCTGCATTGGATGCGGATCCCCAA
CCAATTG
F:CAGTGGTTTTAATGGATCCTTTGGCT
CAAGCATGG
R:CCATGCTTGAGCCAAAGGATCCATT
AAAACCACTG
F:CAATTGGTTGGGGATCCGCATCCAA
TGCAGGG
R:CCCTGCATTGGATGCGGATCCCCAA
CCAATTG
F:CAGTGGTTTTAATGGATCCTTTGGCT
CAAGCATGG
R:CCATGCTTGAGCCAAAGGATCCATT
AAAACCACTG
F:CAATTGGTTGGGGATCCGCATCCAA
TGCAGGG
R:CCCTGCATTGGATGCGGATCCCCAA
CCAATTG
F:CAGTGGTTTTAATGGATCCTTTGGCT
CAAGCATGG
R:CCATGCTTGAGCCAAAGGATCCATT
AAAACCACTG

F-forward primer; R-reverse primer

Table 2. List of plasmids and primers constructed by Quickchange mutagenesis,
based on the parent plasmid, pSD639.
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2.2 Protein Expression and Cell Lysis
The relevant expression plasmids for the various TDP-43 constructs were
transformed into and expressed from the E. coli strains, MM294 and BL21DE3.
For a large cell growth, one transformed E. coli colony was added to 25 mL of liquid
LBamp and incubated for 3 h (37°C, shaking) until a density of 0.1 absorbance at
600 nm (A600) was reached. Ten µL of a 10x dilution of this growth was added to 1
litre 2xYTamp media (Yeast Extract Tryptone media) and grown overnight at 30°C,
shaking, to an A600 of 0.6. Protein expression was induced by adding 120 mg of
IPTG and growth continued for 6 h (37°C, shaking). Cells were collected by low
speed centrifugation in a Beckman JA-9.1 rotor (6k rpm, 10 min) and resuspended
in 50 mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 8.0, buffer to a 50% suspension
and stored at -80°C for later use.
The induced cells were lysed using a French Pressure Cell. Two mL of the
50% induced cell suspension were added to 30 mL of lysing buffer, containing 50
mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 8.0, plus 1 mM PMSF. The cell lysate
was centrifuged at low speed in a Beckman JA-25.5 rotor (10k rpm, 10 min, 4°C),
the supernatant was collected and centrifuged again at high speed (38k rpm, 90
min, 4°C) in a Beckman 70.1Ti rotor. If the TDP-43 polypeptide was soluble, the
final supernatant was stored at -80°C for future experimentation. Some of the
variants expressed as inclusion bodies and were initially stored as pellets.

40

2.3 Protein Expression by Mini-Induction
For some of the experiments, induced cell extracts were required in small
amounts. A transformed colony was added to 5 mL of LBamp and grown in a 37°C
water bath, shaking. At an A600 of 0.1, the cultures were induced with 0.55 mM
IPTG and allowed to grow to stationary phase. The induced cells were centrifuged
and resuspended in 1x SDS-PAGE sample buffer with 50 mM DTT and boiled for
5 minutes. These extracts were frozen at -20°C for later use.

2.4 TDP-43 Construct Purification
TDP-43 is a highly aggregation-prone protein and the purification of the
overexpressed constructs for this work was complicated. The following are the
different procedures developed to prepare the TDP-43 variants that were purified
for this work. Proteins were analyzed by SDS-PAGE using 15% polyacrylamide
gels and a Tris-Tricine running buffer (96). SDS protein samples were prepared
with denaturing sample buffer with 50 mM DTT (SB+). The protein bands were
visualized by staining the gel with Coomassie Blue G. The protein concentration
at various steps was determined by the Bio-Rad Protein Assay (reagent from BioRad Laboratories) by comparing sample absorbance at 595 nm to a calibration
curve of known BSA concentrations.

2.4.1 HT-NR purification—This protein was soluble after initial centrifugation. The
first step in purification was a 40% saturated ammonium sulfate (NH4SO4)
precipitation, achieved by adding 100% saturated NH4SO4 directly to the retrieved
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supernatant. At 40% saturation, the majority of the HT-NR polypeptide precipitated
and after centrifugation at 4°C in a Beckman JA-25.5 rotor, the NH4SO4
supernatant was removed and the pellet was dissolved in 50 mM Tris-HCl, 100
mM NaCl, 10 mM imidazole, pH 8.0. This buffer was selected because it is
compatible with an immobilized metal affinity column.

Before loading the

resolubilized protein on the column, it was centrifuged at 13,000 rpm for 20 min in
a desktop centrifuge to remove any insoluble particles.
A column containing 10 mL of Chelating Sepharose was charged with Ni 2+
(Ni2+ affinity column) to utilize the His6-tag on HT-NR. At room temperature, the
HT-NR solution was loaded onto the column and the flowthrough (FT) was
collected. Since the HT-NR polypeptide contains the RNA-binding domain, the
column was washed with 10 column volumes of 200 mM NaNO 3 and 1 M NaCl to
dissociate any bound nucleotides. To elute the bound protein, an elution buffer
containing 50 mM Tris-HCl, 100 mM NaCl and 500 mM imidazole, pH 8.0, was
added in 5-mL aliquots, with 5-mL fractions collected. The fractions containing the
highest levels of HT-NR were identified by SDS-PAGE, pooled and adjusted again
to 40% saturated NH4SO4 to precipitate the protein as before. After centrifugation,
the resulting pellet was collected and redissolved in 2 mL of 750 mM arginine
hydrochloride (ArgHCl), 50 mM Tris-HCl, 1 mM DTT, pH 8.0 to concentrate the
HT-NR and prepare it for further purification. ArgHCl was added to disrupt any
unwanted protein interactions that were maintained through the first column and
separate the contaminating species through a second purification column, gel
filtration.
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A 200 mL column containing Sephacryl S-200 resin (S200) was equilibrated
with the 750 mM ArgHCl, 50 mM Tris-HCl, 1 mM DTT, pH 8.0, buffer and the
protein sample was loaded on the column and maintained at 4°C. The same buffer
was used to run the column, collecting 1-mL fractions at 2 mL/h. As before, the
fractions with the highest level of protein were identified by SDS-PAGE, pooled
and precipitated with 40% saturated NH4SO4. The precipitate was centrifuged as
before and redissolved in 50 mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 8.0, buffer
and centrifuged again in preparation for the final purification column.
A 23 mL Q-Sepharose ion exchange (IX) column connected to an
AKTAexplorer HPLC was equilibrated with 50 mM Tris-HCl, 1 mM EDTA, 1 mM
DTT, pH 8.0, at room temperature. The redissolved HT-NR protein was loaded
onto the column and eluted with a 6-column volume 0-1 M NaCl gradient in 50 mM
Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 8.0. The presence of eluted protein was
monitored by reading absorbance at 280 nm (A280) of each fraction, further
identified by SDS-PAGE, pooled and dialyzed against 50 mM Tris-HCl, 1 mM
EDTA, 1 mM DTT, pH 8.0, for storage at -80°C as this final step resulted in pure
HT-NR protein.

2.4.2 HT-G purification—The HT-G polypeptide was purified by Dr. Stan Dunn and
as undergraduate project work by Christina Chung, Thamiya Vasanthakumar and
Jethro Kwong (97, 98). Briefly, overexpression of HT-G in E. coli formed an
inclusion body that sedimented in the low speed pellet after lysis. The inclusion
body was washed and resolubilized in 4 M guanidine hydrochloride (GuHCl), 10
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mM Tris-HCl, 0.1 mM EDTA, 10 mM imidazole, pH 8.0 then loaded onto a Ni 2+
affinity column. To facilitate refolding of the denatured HT-G, the column was
washed with 100 mM Tris-HCl, 30% dimethylformamide, 10 mM imidazole, pH 8.0,
then with 100 mM Tris-HCl, 10 mM imidazole, pH 8.0. The column was washed
again with 750 mM ArgHCl, 100 mM Tris-HCl, 10 mM imidazole, pH 8.0, and finally
750 mM ArgHCl, 100 mM Tris-HCl, 250 mM imidazole, pH 8.0, to elute the bound
protein. The eluted protein was pooled and stored at -80°C.
HT-G was dialyzed at room temperature against 1 mM trifluoroacetic acid
(TFA) in ddH2O, then 0.1 mM TFA. Since TFA is acidic, a further dialysis was
done with 25 mM Tris-HCl, 0.1 mM TFA and 1 mM TCEP, pH 7.5 or 25 mM TrisHCl, 25 mM Tricine and 1 mM TCEP, pH 7.3, to neutralize the solution for further
work. Dialysis against 25 mM Tris base, 50 mM Tricine, 1 mM TCEP, pH 7.5 also
maintained HT-G solubility and was used in some work.

2.4.3 C-terminal domain mutant purification—Two of the deletion mutant
polypeptides, HT-G386-416 and HT-G386-406, were purified. Much of the aggregation
prone region of the C-terminal domain was deleted and therefore after cell lysis,
the two constructs were soluble after the high speed spin. Both were purified by
the same procedure as follows.
After centrifugation, the supernatants were 40% saturated NH4SO4
precipitated, centrifuged at 13,000 rpm at 4°C and the pellet was resuspended in
50 mM Tris-HCl, 100 mM NaCl and 10 mM imidazole, pH 8.0, for loading on a Ni2+
affinity column. The bound protein was washed with 5 column volumes of 50 mM
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Tris-HCl, 100 mM NaCl, 10 mM imidazole, pH 8.0, then eluted as previously
described in the HT-NR purification procedure. Following elution from the Ni2+
affinity column, the fractions that contained the most protein were pooled and
dialyzed against 50 mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 8.0. Next, the
samples were loaded onto the IX Q-column, as previously described. Following
elution, the fractions containing the polypeptides of interest were pooled, 70%
saturated NH4SO4 precipitated and the pellets were redissolved in 25 mM Tris
base, 50 mM tricine, 0.5 mM TCEP, pH 7.5. The two HT-G variants were purified
at this point and were stored for future analysis.

2.4.4 HT tag purification—A volume of cleaved and Ni2+ affinity column purified HT
tag was attained from Jethro Kwong, a member of the Dunn Lab. This was
dialyzed against 50 mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH 8.0, and loaded
onto the IX Q-column, as described in section 2.4.1.

Following elution, the

fractions containing HT were pooled, 70% saturated NH4SO4 precipitated and the
pellet was redissolved in 25 mM Tris base, 50 mM tricine, 0.5 mM TCEP, pH 7.5,
then stored for later use.

2.5 Western Blot
Through many stages of this work, Western blots were used to verify the
presence of TDP-43 polypeptides. The standard methods for Western blotting
were conducted as previously described (99).
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The samples were run by SDS-PAGE long enough for the dye front to run
off the 15% polyacrylamide gel.

The proteins were then electrophoretically

transferred to an Immobilon polyvinylidene fluoride (PVDF) membrane at 0.25 A
for 1 h in a carbonate blot buffer (99). The blotted membrane was transferred to a
blocking buffer containing 3% BSA in blot rinse buffer (10 mM Tris-HCl, 150 mM
NaCl, 1 mM EDTA, 0.1% Tween 20 and 0.04% sodium azide, pH 7.4) and
incubated for at least 2 h at room temperature while shaking. The membrane was
then rinsed 3 times in plain blot rinse buffer for 10 min. Next, the buffer was
exchanged for blot rinse buffer containing 0.3% BSA, the primary antibody was
added at a dilution of 1:5,000 and the membrane was incubated for 2h at 23°C or
overnight at 4°C. Two polyclonal rabbit antibodies from Sigma-Aldrich were used
to detect TDP-43. The first was an anti-N-terminal antibody, with an immunogen
of a synthetic peptide composed of residues 75-90 of TDP-43 (Product Number:
SAB4200006). The second was an anti-C-terminal antibody, with an immunogen
of a synthetic polypeptide composed of residues 355-369 of TDP-43 (Product
Number: T1580). After a 2 h incubation at room temperature, the membrane was
washed again with rinse buffer, exchanged with 0.3% BSA buffer and the
secondary antibody (alkaline phosphatase conjugated goat anti-rabbit IgG,
Jackson ImmunoResearch Laboratories) was added at a dilution of 1:5,000. The
membrane was incubated for 1h at 23°C then washed again with rinse buffer.
Briefly, the alkaline phosphatase was reacted by incubating the membrane in 10
mL of 100 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 9.5, with 80 µL of BCIP
solution (20 mg/mL in 100% dimethylformamide) and 60 µL NBT solution (50
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mg/mL in 70% dimethylformamide). The membrane was left to react until the
desired level of detection of the alkaline phosphatase was reached, approximately
10 minutes.

2.6 Far Western Blot
In this method, the proteins to be blotted were expressed in 5-mL liquid
cultures of BL21 E.coli.

After induction by IPTG, samples were created by

centrifuging a volume of the liquid cell culture and resuspending the cells in 1xSB+
and placing in a boiling water bath for 3-5 min. The cell extracts were analyzed by
SDS-PAGE to begin the process of equalizing the loading of the desired proteins
through subsequent dilutions and SDS-PAGE. Once the desired loading amounts
were detected, the samples were stored at -20°C for use in this analysis.
Probe proteins were labelled with

125I

by Dr. Stan Dunn using the Iodogen

procedure (100).
The blots were prepared as previously described using Immobilon
membrane. Following blocking and rinsing, the membranes were transferred into
0.3% BSA blot rinse buffer and the radioactive probe was added at 50,000-100,000
dpm/mL.

After an overnight incubation at room temperature, the blots were

washed for 10 min to remove any unbound probe and air dried. Finally, the blots
were visualized with a Storm 820 phosphorimager (Amersham Biosciences).
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2.7 Sedimentation Equilibrium and Velocity
The sedimentation experiments were conducted in a Beckman XLA
Analytical Ultracentrifuge in an An60 Ti rotor.
For sedimentation equilibrium (SE), samples were loaded in a 6-channel
centerpiece and maintained at 4°C.

The loaded protein concentrations had

absorbances between 0.2-0.5 at A280 and were sedimented at 12,000-24,000 rpm,
depending on the experiment. The time allotted for sedimentation equilibration
after acceleration also depended on the experiment but all scans had radial
intervals of 0.003 mm and 10 replicates.
The SE data was fit to a single species model using GraphPad Prism 5.
The distribution is described by the equation:
ѡ2

𝐶 = 𝐶𝑜 ∙ exp [2𝑅𝑇 ∙ 𝑀𝑊𝑒𝑥𝑝 (1 − 𝜐̅ 𝜌) ∙ (𝑥 2 − 𝑥𝑜2 )] + 𝐼𝑜

Equation 1

where C is the concentration at radius x, with a concentration C o at reference
radius xo, ѡ is the angular velocity of the rotor, the calculated molecular weight of
the protein is MW exp, 𝜐̅ is the partial specific volume of the analyzed protein, ρ is
the solvent density, R is the gas constant (8.314 x 107 erg ∙ mol

−1

−1

∙ K ), T is

temperature in Kelvin and Io is the baseline correction.
For sedimentation velocity (SV), samples were loaded in a 2-channel
centerpiece and maintained at 4°C.

The loaded protein concentrations had

A280=0.2-0.5 and were sedimented at 45,000 rpm. Scans were taken every 10
minutes for a total of 30 scans, at a radial interval of 0.003 mm with 5 replicates.
The sedimentation spectra were analyzed by the program Sedfit (downloaded from
www.analyticalultracentrifugation.com) (101).
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2.8 Transfections and Colocalization
To complement the in vitro studies, in vivo colocalization studies with the
same TDP-43 domains were carried out by Cheryl Leystra-Lantz and Dr. Cristian
Droppelmann in the Strong Lab. Briefly, four plasmids expressing fluorescently
labelled NR and G polypeptides were constructed: GFP-NR, mCherry-NR, GFP-G
and mCherry-G.

The plasmids were isolated by miniprep (Invitrogen) for

transfection into HEK293T cells.
To visualize in vivo binding of NR and G by confocal microscopy,
cotransfections with GFP-NR/mCherry-G or mCherry-NR/GFP-G were performed.
The cells were plated at 1.25x105 cells/dish in 35 mm confocal dishes (MatTek).
One µg of each plasmid was incubated with Lipofectamine 2000 at a 1:3 ratio and
transfection was carried out as per the manufacturer’s protocol. The cells were
allowed to grow for 48 h then fixed with 4% paraformaldehyde paraformaldehyde
in PBS for 10 minutes, washed in PBS and then visualized using the Meta510
Confocal Microscope (Robarts Confocal Imaging Facility) at 600x magnification.
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Chapter 3: Results
3.1 TDP-43 Variant Plasmid Cloning
To generate materials for studying interdomain interactions in TDP-43, a
plasmid library was created for this work that expressed variants of TDP-43
including individual domains, truncations or point mutations, as described in
Chapter 2. The expressed TDP-43 has 416 amino acids and was isolated from
human brain (36). All variants were N-terminally tagged with a His6-Thioredoxin
(HT) tag and were induced in the E. coli strain BL21DE3. Figure 11 schematically
shows the library of expressed polypeptides. Throughout this work, the proteins
will be referred to as their descriptive “Name” and not the plasmid number. The
proteins HT-NRG, HT-NR, HT-RG, HT-N, HT-R and HT-G all express various
combinations of the wild-type TDP-43 domains, as indicated by their names.
Many variants of the C-terminal domain were also created to see how
mutations or phosphorylation affected possible interdomain interactions. HT-GM337V expressed the C-terminal domain with the common familial ALS mutation,
Met337Val.
The HT-G-Δ407 construct is a truncated C-terminal domain, missing
residues 407-416.

This construct was created to eliminate the extreme C-

terminus, including the key Ser409/410 residues that were phosphorylated in
aggregates.
The constructs HT-G-S409D, HT-G-S410D and HT-G-SS409DD express
mutations to the C-terminal domain that introduce an Asp (D) residue at the
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phosphorylatable Ser409/410.

These mutations introduce a phosphomimetic

residue that mimic the effects of phosphorylation on interaction.
The remaining constructs were made to introduce further alterations to the
previously mentioned C-terminal domain proteins. Two truncations were made
that deleted much of the C-terminal domain, expressing only residues 386-416 or
399-416. Similar deletions were also made to some of the previously mentioned
mutants. Additionally, the last two residues, Asn415 and His416, were deleted
from two of the C-terminal domain constructs.
To verify that the new TDP-43 constructs contained the expected domains
of TDP-43 and would blot sufficiently, SDS cell extracts of most of the constructs
were blotted and probed with antibodies for the N-terminus and C-terminus of TDP43. The HT-G constructs pKD019-026 were not blotted because the immunogen
site was within the deleted residues. Figure 12 shows the developed blots. All
polypeptides were detectable by the appropriate antibody. HT-R was not detected
by either antibody as expected. There was some background signal with the
antibodies but this was likely due to sample loading, degradation products or nonspecific binding by either the primary or secondary antibody.
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Figure 11. Schematic diagram of the TDP-43 variants used in this work. The
calculated molecular weight for each expressed protein is below each diagram.
The red marker shows the location of an ALS associated mutation. The green
marker shows the location of a phosphomimetic mutation. Unless indicated by
subscript position numbers, HT-G constructs contain the full C-terminal domain,
modified with the further descriptors.
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Figure 12. TDP-43 constructs detected by Western blot. SDS cell extracts were
prepared, blotted and probed with antibodies for the N-terminus and C-terminus of
TDP-43. The blotted constructs are labelled above. The expected bands are
starred (*). Any other present bands are likely due to non-specific binding by the
antibodies used, oligomeric species of the constructs or degradation species of the
constructs.
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3.2 Polypeptide Purification
Pure proteins were required for some of the experiments in this work and
were purified as outlined in Chapter 2.
The first, HT-NR, was purified through a series of precipitations and
columns, as demonstrated in Figure 13. After lysis and centrifugation, the majority
of the expressed HT-NR was soluble (Figure 13A). It was precipitated by 40%
saturated NH4SO4 and redissolved in 50 mM Tris-HCl, 100 mM NaCl and 10 mM
imidazole, pH 8.0, buffer for loading on the Ni2+ affinity column (Figure 13B). At
this point, there was a possibility that RNA or DNA might still be bound to the RNAbinding domain. Therefore, the bound HT-NR was washed with 1 M NaCl and 200
mM NaNO3, a chaotropic agent, in 50 mM Tris-HCl, 100 mM NaCl and 10 mM
imidazole, pH 8.0, to disrupt the nucleotide interactions. RNase and DNase were
digests were attempted, however there was some interaction with the column and
elution of the nucleases overlapped with the eluted HT-NR (data not shown). The
bound protein was eluted with 50 mM Tris-HCl, 100 mM NaCl and 500 mM
imidazole, pH 8.0, and the fractions with HT-NR were pooled and precipitated by
40% saturated NH4SO4 for transition into 750 mM ArgHCl, 50 mM Tris-HCl, 1 mM
DTT, pH 8.0 (Figure 13C). ArgHCl was used to solubilize the more concentrated
HT-NR without structure denaturation and to assist in breaking up any proteinprotein interactions that survived the previous column. The HT-NR was purified
further by running through a gel filtration column (S200), equilibrated with 750 mM
ArgHCl, 50 mM Tris-HCl, 1 mM DTT, pH 8.0 (Figure 13D).

In consecutive

fractions, two peaks of HT-NR were observed: the first, centred around fraction 59,
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Figure 13. Purification of the HT-NR polypeptide. The red arrow indicates the band
of interest, HT-NR. A) SDS samples of the cell lysate, centrifugation supernatants
(SN) and pellets (P) and initial 40% saturated NH4SO4 precipitation. The low
speed and high speed pellets were resuspended in an equal volume to the
supernatant before sampling. B) Sample of HT-NR loaded onto the Ni2+ affinity
column and samples from the FT, wash and eluted protein. C) SDS samples of
the 40% saturated NH4SO4 SN and redissolved P of the pooled HT-NR eluted from
the Ni2+ affinity column.

D) SDS samples of the loaded HT-NR and eluted

fractions from the S200 gel filtration column. The pooled fractions are indicated by
the bracket. E) SDS samples of the eluted HT-NR from the IX column. The pooled
fractions are indicated by the bracket. F) An example of the final purified HT-NR
for use in further study.
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coeluted with an unknown E. coli protein and the second, centred around fraction
66, contained predominantly HT-NR. This second peak was pooled, precipitated
by 40% saturated NH4SO4, then redissolved and dialyzed in 50 mM Tris-HCl, 1
mM EDTA, 1 mM DTT, pH 8.0, for final purification by IX (Figure 13E). HT-NR
eluted between 250-350 mM NaCl and the most concentrated samples were
pooled and stored for later use. Figure 13F shows the final purified HT-NR protein.
As previously mentioned, the HT-G purification protocol was established by
Dr. Stan Dunn, Christina Chung, Thamiya Vasanthakumar and Jethro Kwong.
Many different salts and buffering conditions were unsuccessful at preventing
precipitation of HT-G.

The established procedure that successfully achieved

soluble and purified HT-G was in a buffer containing 750 mM ArgHCl. This
construct contains the aggregation prone C-terminal domain of TDP-43 and
ArgHCl was used to solubilize HT-G (102). The high concentration of ArgHCl was
not an ideal buffer condition for interaction studies, so it was necessary to find
another buffer condition. TFA is a known additive for dissolving and solubilizing
aggregation prone proteins, including β-amyloid (103). HT-G remained soluble
after room temperature dialysis into 1 mM TFA, then 0.1 mm TFA in ddH2O (Figure
14A). To increase the pH, the TFA solubilized HT-G was buffered with Tris-HCl,
pH 8.0, at various concentrations to determine solubility (Figure 14B). Adding 25
mM Tris-HCl, pH 8.0, maintained maximum solubility of HT-G and 1 mM of
neutralized TCEP was added (Figure 14C). For some experiments, a buffer with a
higher ionic strength was suitable since many proteins require such conditions to
adopt proper structures and interactions. Tricine is similar to Tris in structure
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Figure 14. Solubility trials of HT-G. A) SDS-samples demonstrating HT-G in
solution before (Arg750) and after dialysis into 0.1 mM TFA and centrifugation at
13,000 rpm for 15 min (TFA0.1). B) SDS samples of the tests for HT-G solubility
after dialysis into 25, 50, 75 and 100 mM Tris-HCl, pH 8.0 (Tris25-100). Each solution
was centrifuged at 13,000 rpm for 15 min after dialysis.

C) SDS samples

demonstrating the solubility of HT-G after addition of 1 mM neutralized TCEP
(Tris25TCEP1).

D) SDS samples demonstrating that HT-G in 0.1 mM TFA

remained soluble after dialysis against 25 mM Tris-HCl, 25 mM tricine, 1 mM
TCEP, pH 7.3, and centrifugation at 13,000 rpm for 15 min (Tris25Tric25TCEP1). E)
SDS samples showing that HT-G in 750 mM ArgHCl was soluble after dialysis
against 25 mM Tris base, 50 mM tricine, 1 mM TCEP, pH 7.5, and centrifugation
at 13,000 rpm for 15 min (Tris25Tric50TCEP1).
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but it is an acid rather than a base and has a more spread out charge distribution.
HT-G in 0.1 mM TFA was dialyzed overnight into 25 mM Tris-HCl, 25 mM tricine,
1 mM TCEP, pH 7.3, and remained soluble (Figure 14D). TFA was not included
in this dialysis because it is believed to bind directly to the protein and is not easily
removed. In an additional sample preparation, ArgHCl solubilized HT-G was
dialyzed overnight against 25 mM Tris base, 50 mM tricine, 1 mM TCEP, pH 7.5,
without any intermediate TFA dialysis. HT-G was soluble under this condition and
used in further studies (Figure 14E).
The two polypeptides HT-G386-416 and H-G386-406 were purified through a
series of precipitations and columns, as demonstrated in Figure 15A-D and Figure
15E-H, respectively. Both were purified by the same method. After lysis and
centrifugation, the majority of the expressed polypeptides were soluble (Figure 15A
and E). The high speed supernatants were precipitated by 40% saturated NH4SO4
and redissolved in 50 mM Tris-HCl, 100 mM NaCl and 10 mM imidazole, pH 8.0,
buffer for loading on the Ni2+ affinity column (Figure 15B and F). Samples of the
FT, wash and eluted protein are shown in Figure 15B and F. The fractions that
contained the highest amount of eluted protein were dialyzed against 50 mM TrisHCl, 1 mM EDTA, 1 mM DTT, pH 8.0, for final purification by IX (Figure 15C and
G).

Both HT-G mutants eluted between 230-360 mM NaCl and the most

concentrated samples were pooled and stored for later use. Figure 15D and H
show the final purified HT-G386-416 and HT-G386-406, respectively.
Finally, a purification of HT was performed to have a negative control for
any influence of the tag during interaction experiments. The sample acquired from
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Figure 15. Purification of HT-G386-416 and HT-G386-406. A-D are for HT-G386-416 and
E-H are for HT-G386-406. The red arrow indicates the band of interest. A and D)
Cell lysate, centrifugation supernatants (SN) and pellets (P). The low speed and
high speed pellets were resuspended in an equal volume to the supernatant before
sampling. B and F) SDS samples of the NH4SO4 SN and pellet (Ni2+ affinity load)
and samples from the FT, wash and eluted protein from the Ni2+ affinity column. C
and G) SDS samples of the eluted HT-G386-416 and HT-G386-406 from the IX column.
The pooled fractions are indicated by the bracket. D and H) An example of the
final purified HT-G386-416 and HT-G386-406 for use in further study.
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Jethro Kwong was dialyzed against 50 mM Tris-HCl, 1 mM EDTA, 1 mM DTT, pH
8.0, and loaded onto the IX column (Figure 16A). HT mutants eluted between 240300 mM NaCl and the most concentrated samples were pooled, 70% saturated
NH4SO4 precipitated and dialyzed against 25 mM Tris base, 50 mM tricine, 0.5 mM
TCEP, pH 7.5. Figure 16B shows the final purified HT.

3.3 Far Western Blot
3.3.1 Interactions with TDP-43 domains—The Far Western blot technique has
been widely used to visualize protein-protein interactions (104). To visualize the
interactions, SDS-extracts of E. coli with the induced TDP-43 variants were
separated by SDS-PAGE, blotted and incubated with a radio-labelled probe that
was a suspected interactor. Purified HT-NR and HT-N were both labelled with 125I,
referred to as

125I-HT-NR

and

125I-HT-N.

HT-N was purified by Jethro Kwong. A

Rhodobacter capsulatus F1-ATPase delta subunit, also fused to HT (HT-δ), is
included in this experiment as a negative control. The background E. coli proteins
in the extracts acted as further controls for off-target binding by the probe. The
first blots were to test the interaction capability of

125I-HT-NR

with the panel of

wildtype TDP-43 domain variants. Figure 17B shows the exposed blot and the
corresponding Coomassie stained gel.

125I-HT-NR

strongly with HT-NRG, HT-RG, HT-R and HT-G.

was observed to interact
A weaker interaction was

observed with HT-NR and almost no interaction was observed with HT-N. There
was no interaction with HT-δ. Following this result, the interactions of

125I-HT-NR

and 125I-HT-N were compared (Figure 17C). The interactions observed with the
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Figure 16. Purification of the HT polypeptide. A) SDS samples of the eluted HT
fractions from the IX column. The pooled fractions are indicated by the bracket.
B) Final sample of purified HT.
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125I-HT-NR

probe were similar to those in Figure 17B. However, much weaker 125I-

HT-N interactions were observed, with only faint signals for HT-NRG, HT-RG, HTR and HT-G. These results indicated an interaction by either the N-terminal or
RNA-binding domain with the C-terminal domain of TDP-43. The weaker results
with

125I-HT-N

suggested a stronger influence by the RNA-binding domain for

binding with the C-terminal domain.

3.3.2 Interactions with C-terminal domain mutants—The C-terminal domain
mutants were blotted and incubated with the probes to see how mutations or
phosphomimetics affected interaction. Figure 18A shows the results for interaction
with

125I-HT-NR.

Strong interactions were observed with HT-G (Figure 17) and

with HT-G-M337V. The truncation in HT-G-Δ407 greatly reduced the interaction.
A reduction in interaction was also observed with the phosphomimetic variants.
HT-G-S409D had a weaker interaction signal than HT-G-S410D but similar to that
of the double phosphomimetic. These results indicate that the extreme C-terminus
of the C-terminal domain is critical for interaction. Two sets of repetitive blots were
performed to verify these results (Figure 18B and C).

3.3.3 Interactions with C-terminal domain deletions—To further analyze the
importance of the extreme C-terminal domain to binding, the constructed deletion
mutants were analyzed by Far Western blotting (Figure 19). The HT-G positive
control showed the expected binding with

125I-HT-NR.

There was no observable

binding with any of the deletion mutants included. This was a surprising result
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Figure 17. Far Western blot results for the panel of wild-type domains of TDP-43.
A) Schematic diagram of the labelling of the TDP-43 domains. B) Shows the
Coomassie blue stained gel and exposed blot.

Ten microliters of the same

samples were used for both the stained and transferred gels. The TDP-43 variants
were blotted and incubated overnight with the probe,

125I-HT-NR.

The radioactive

signal was observed using a phosphorimager. C) The two sets of TDP-43 variants
were blotted on the same PVDF membrane, then the membrane was cut in half
for separate incubation with either

125I-HT-NR

or

125I-HT-N.

control. The signals were detected using a phosphorimager.

HT-δ is a negative
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Figure 18. Far Western blot results for the C-terminal domain variants. A) Shown
are the Coomassie blue stained gel and exposed blot. The TDP-43 variants were
blotted and incubated overnight with the probe,

125I-HT-NR.

B) and C) show

duplicated sets of the C-terminal domain variants for monitoring reproducibility of
the binding level. The radioactive signal was observed using a phosphorimager.
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Figure 19. Far Western blot results for the C-terminal domain deletion variants.
Shown are the Coomassie blue stained gel and exposed blot. The TDP-43
variants were blotted and incubated overnight with the probe, 125I-HT-NR. HT-G
was included for a positive control and HT-G-Δ407 and HT-δ were included for
negative controls.
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for the constructs HT-G386-416 and HT-G399-416 especially, as they were expected to
maintain some capacity for interaction.

It is possible that the binding region

includes additional residues within the C-terminal domain and those remaining in
these constructs were not sufficient to maintain an interaction to be detected by
this method.
As mentioned in the introductions, TDP-43 is typically reported as a 414
amino acid protein but this work has used a 416 amino acid isoform. It was of
interest to create the C-terminal domain variant with the last two residues deleted
(HT-G-ΔNH, comparable to the 414 amino acid TDP-43) and compare its binding
with 125I-HT-NR to the larger isoform. In Figure 20A, three dilution levels of the Cterminal domain variants were blotted. As previously observed, HT-G-S409D had
reduced binding compared to HT-G. HT-G-ΔNH appeared to have increased
binding compared to HT-G that was reduced in the phosphomimetic, HT-G-S409DΔNH. Visually, HT-G-ΔNH appeared to have 2x stronger binding with the probe
than HT-G. This was verified through repeated sets of HT-G and HT-G-ΔNH in
Figure 20B.

3.4 Analytical Ultracentrifugation
Analytical ultracentrifugation (AUC) is a useful tool for analyzing the solution
behaviour of proteins including shape and interactions.

Both sedimentation

equilibrium (SE) and sedimentation velocity (SV) were used in this work to further
characterize the TDP-43 variants and their interactions.
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Figure 20. Far Western blot results for the C-terminal domain variant, HT-G-ΔNH.
Shown are the Coomassie blue stained gel and exposed blot.
variants were blotted and incubated overnight with the probe,

The TDP-43

125I-HT-NR.

HT-δ

was included as a negative control. A) The four blotted variants were loaded at
three dilution levels: 1 to 1, 1 to 2 and 1 to 4. B) The 1 to 1 and 1 to 2 samples of
HT-G and HT-G-ΔNH were blotted in triplicate to verify the reproducibility of the
detected interaction level.
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3.4.1 Sedimentation velocity of His6-Thioredoxin—To verify that the HT tag would
not form homodimers, SV experiments were done to observe any concentration
dependant dimer formation (Figure 21). At increasing concentrations of purified
HT (1.7 mg/mL, 2.8 mg/mL and 5.6 mg/mL), there was no change in the S obs for
the major sedimenting species. Therefore, there was no dimerization of HT and it
is a reasonable tag for further studies.

3.4.2 Classification of individual TDP-43 variants—Purified HT-NR and HT-G were
first analyzed separately by SE and SV to establish the behaviour of each.
Purified HT-NR was dialyzed into 50 mM Tris-HCl, 0.1 mM EDTA, 1 mM
TCEP, pH 8.0 and diluted to A280=0.25. The protein was loaded into the centrifuge,
as described in Experimental Procedures, for both SE and SV. HT-NR sedimented
as a single, monomeric species in both SE and SV experiments. From SE, the
experimental molecular weight (MW exp) was calculated to be 45.6 kDa by fitting
the data to a global single ideal species model (Figure 22A).

HT-NR also

sedimented largely as a single species with an observed sedimentation coefficient
(Sobs) =2.08 S and with a fitted MW exp=42.6 kDa (Figure 22B). The smaller peak,
corresponding to a faster sedimenting species, was likely a small amount of HTNR homodimer. This is consistent with the Far Western blots that had a low level
of 125I-HT-NR interaction with HT-NR (Figure 17).
Purified HT-G was dialyzed into 25 mM Tris-HCl, 0.1 mM TFA, 1 mM TCEP
and diluted to A280=0.25. The protein was loaded into the centrifuge, as described
in Experimental Procedures for both SE and SV. HT-G sedimented as a single,
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Figure 21. Sedimentation velocity experiments for various concentrations of HT.
The cells were loaded with 1.7 mg/mL, 2.8 mg/mL or 5.6 mg/mL of purified HT in
into 50 mM Tris-HCl, 0.1 mM EDTA, 1 mM TCEP, pH 8.0. HT 𝜐̅ =0.7383 mL/g,
ρ=0.9984 g/mL and η=1.009 cP. All samples were centrifuged at 45,000 rpm, 4°C
and sedimentation was monitored by A280 every 10 min for 30 scans. The data
were analyzed by Sedfit, using a continuous c(s) distribution model.
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Figure 22. Equilibrium and velocity sedimentation results for HT-NR. A) For SE,
the cell was loaded with 0.22 mg/mL HT-NR in SV to establish the behaviour of
each. Purified HT-NR was dialyzed into 50 mM Tris-HCl, 0.1 mM EDTA, 1 mM
TCEP, pH 8.0and sedimentation was observed by A280 after equilibration at
12,000, 16,000 and 20,000 rpm at 4°C. The data were fit to a global single ideal
species model with a calculated MW exp= 45.6 kDa. The calculated residuals are
shown above the plot. B) For SV, the cell was loaded with HT-NR at 0.23 mg/mL,
centrifuged at 45,000 rpm at 4°C and sedimentation was monitored by A 280 every
10 min for 30 scans. The data were analyzed by Sedfit, using a continuous c(s)
distribution model.

A single species with Sobs=2.08 S and with a predicted

MW exp=42.6 kDa. Both SE and SV were analyzed with 𝜐̅ =0.7349 mL/g, ρ=1.00145
g/mL and η=1.017 cP. C) Summary table of the information from the SE and SV
experiments. The polypeptide MW was calculated from the amino acid sequence
and assumed removal of the N-terminal Met.

72

73
monomeric species in both SE and SV experiments. From SE, the MWexp was
calculated to be 22.2 kDa by fitting the data to a global single ideal species model
(Figure 23A). In SV, HT-G sedimented as a single species with a sedimentation
coefficient=1.60 S and with a fitted MWexp=20.8 kDa (Figure 23B). It is of note
that the fitted molecular weights for both SE and SV were much lower than the
calculated molecular weight.
3.4.3 Sedimentation velocity of combined TDP-43 domains—SV experiments were
then performed to see if the two isolated fragments of TDP-43 interact when mixed
in solution. In the first experiment (Figure 24A), HT-NR and HT-G were dialyzed
into 25 mM Tris-HCl, 0.1 mM TFA, 1 mM TCEP, pH 7.3 and the individual
polypeptides and the mixture were compared.

To detect transient or weak

interactions, the slower sedimenting HT-G was added in excess to HT-NR to
maximize the effect of weak binding by HT-NR as it sediments through HT-G. The
peaks corresponding to the HT-G boundary overlap and have similar Sobs (1.583
S or 1.603 S). In the combined experiment, the peak for HT-NR (2.267 S) was
shifted to a larger Sobs compared to HT-NR only (2.174 S). This suggested that
there was residual binding with HT-NR and HT-G which increased the
sedimentation rate of HT-NR.

HT-G was not similarly affected because it

sedimented largely without HT-NR influence. There is again a small peak in HTNR alone corresponding to a faster sedimenting species that is likely a small
amount of HT-NR homodimer (S=3.472 S). In the combined run, there is a similar
faster sedimenting species that is shifted (S=3.560 S), likely due to interaction with
HT-G. The 25 mM Tris-HCl, 0.1 mM TFA, 1 mM TCEP, pH 7.5, buffer was very
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Figure 23. Equilibrium and velocity sedimentation results for HT-G. A) For SE,
the cell was loaded with 0.19 mg/mL HT-G in 25 mM Tris-HCl, 0.1 mM TFA, 1 mM
TCEP and sedimentation was observed by A280 after equilibration at 14,000,
16,000, 18,000 and 20,000 rpm at 4°C. The data were fit to a global single ideal
species model with a calculated MW exp=22.2 kDa. The calculated residuals are
shown above the plot. B) For SV, the cell was loaded with HT-G at 0.19 mg/mL,
centrifuged at 45,000 rpm at 4°C and sedimentation was monitored by A 280 every
10 min for 30 scans. The data were analyzed by Sedfit, using a continuous c(s)
distribution model.

A single species with Sobs=1.60 S was observed, with a

predicted MW exp=20.8 kDa. Both SE and SV were analyzed with 𝜐̅ =0.7142 mL/g,
ρ=0.9991 g/mL and η=1.009 cP. C) Summary table of the information from the SE
and SV experiments. The polypeptide MW was calculated from the amino acid
sequence and assumed removal of the N-terminal Met.
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low in ionic strength which may not promote protein interactions. Furthermore,
while the concentration of TFA was low, it might also affect such interactions.
Therefore, it was of interest to change to a different buffer.
The second experiment (Figure 24B) used 25 mM Tris-HCl, 25 mM tricine,
1 mM TCEP, pH 7.3, as the sample buffer. HT-NR was added in excess to HT-G.
The sample of HT-G in this experiment was solubilized first in ArgHCl, then in TFA.
TFA was left out of the final buffer for SV to reduce the effects of TFA on the
structure and interactions made in solution. The residual TFA after dialysis into
the 25 mM Tris-HCl, 25 mM tricine, 1 mM TCEP, pH 7.3, should not have an effect
on the results. In the combined sample, there was a single sedimenting species
detected with Sobs=1.789 S. This boundary was sedimenting faster than HT-G
alone (Sobs=1.711 S) and slower than HT-NR alone (Sobs=2.366 S). There was
also an even faster sedimenting species at Sobs=3.192 S in the combined sample.
In the third experiment, the polypeptides were dialyzed into 25 mM Tris
base, 50 mM tricine, 1 mM TCEP, pH 7.5. This sample of HT-G was dialyzed
directly from ArgHCl and therefore was not exposed to any TFA to prevent any
structural influence due to TFA binding. HT-G was also added in excess to HTNR to provide the same opportunity for observing weak binding as in the initial
experiment. Figure 24C shows the results for this SV run. Similar to the second
experiment, when HT-NR and HT-G were mixed, a single sedimenting species
was observed with a Sobs=1.697 S, which was again faster than HT-G alone
(Sobs=1.555 S) and slower than HT-NR alone (Sobs=2.124 S). A faster sedimenting
species (Sobs=3.351 S) was again observed in the combined sample.
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Figure 24. Sedimentation velocity results of the HT-NR (solid), HT-G (dashed) and
combined (dotted) in various buffers. A) The cells were loaded with HT-NR (0.12
mg/mL), HT-G (0.25 mg/mL) or Both (0.37 mg/mL), all in 25 mM Tris-HCl, 0.1 mM
TFA, 1 mM TCEP, pH 7.3. The Sobs are shown on the graph. B) The cells were
loaded with HT-NR (0.61 mg/mL), HT-G (0.29 mg/mL) or Both (0.90 mg/mL), all in
used 25 mM Tris-HCl, 25 mM tricine, 1 mM TCEP, pH 7.3. The Sobs are shown on
the graph. C) The cells were loaded with HT-NR (0.18 mg/mL), HT-G (0.18
mg/mL) or Both (0.75 mg/mL), all in used 25 mM Tris base, 50 mM tricine, 1 mM
TCEP, pH 7.5. The Sobs are shown on the graph. SV data were analyzed with HTNR 𝜐̅ =0.7349 mL/g, HT-G 𝜐̅ = 0.7142 mL/g, Both 𝜐̅ =0.7246 mL/g, ρ = 1.0004 g/mL
and η = 1.009 cP.

All samples were centrifuged at 45,000 rpm, 4°C and

sedimentation was monitored by A280 every 10 min for 30 scans. The data were
analyzed by Sedfit, using a continuous c(s) distribution model.
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Again in these experiments, small peaks corresponding to a faster
sedimenting HT-NR homodimer were observed in the HT-NR alone samples.
To test the theory that the extreme C-terminus of TDP-43 is responsible for
binding, two of the deletion mutants were purified for analysis by SV. HT-NR, HTG386-416 and HT-G386-406 were dialyzed against 25 mM Tris base, 50 mM tricine, 0.5
mM TCEP, pH 7.5 and were loaded into the centrifuge. The combination samples
were loaded with a molar excess of the HT-G variants. As a negative control, a
sample of the HT tag was also purified and analyzed by SV. In all experiments,
the HT-G variant or HT was in excess to HT-NR.
Figure 25A shows the results for the SV with HT-G386-416. It was predicted
that this shorter region of the C-terminal domain would form a heterodimer with
HT-NR that would sediment faster than HT-NR alone and would not form the
extended structure as suggested in the previous experiment. In the combined
sample, the strongest boundary sedimenting at S obs=1.392 S was faster than HTG386-416 alone (Sobs=1.065 S) and slower than HT-NR alone (Sobs=2.182 S). A
faster sedimenting peak at Sobs=2.695 S was also present in the combined sample.
Figure 25B shows the results for the SV with HT-G386-406.

It was

hypothesized that this even shorter region of the C-terminal domain would not
participate in any interactions, as observed in the Far Western blot experiments.
Again in the combined sample, a boundary was observed at Sobs=1.241 S that was
sedimenting slightly faster than HT-G alone, Sobs=1.121 S, and slower than HTNR alone, Sobs=2.079 S.
Sobs=2.412 S.

There was again a faster sedimenting species at
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Figure 25. Sedimentation velocity results for the truncated HT-G constructs. A)
The cells were loaded with HT-NR (0.21 mg/mL), HT-G386-416 (0.18 mg/mL) or Both
(0.39 mg/mL), all in 25 mM Tris base, 50 mM tricine, 0.5 mM TCEP, pH 7.5. The
Sobs are shown on the graph. B) The cells were loaded with HT-NR (0.21 mg/mL),
HT-G386-406 (0.18 mg/mL) or Both (0.39 mg/mL), all in 25 mM Tris base, 50 mM
tricine, 0.5 mM TCEP, pH 7.5. C) The cells were loaded with HT-NR (0.21 mg/mL),
HT (0.17 mg/mL) or Both (0.38 mg/mL), all in 25 mM Tris base, 50 mM tricine, 0.5
mM TCEP, pH 7.5. The Sobs are shown on the graphs. SV data were analyzed
with HT-NR 𝜐̅ =0.7349 mL/g, HT-G386-416 𝜐̅ = 0.7282 mL/g, HT-G386-406 𝜐̅ = 0.7304
mL/g, HT 𝜐̅ =0.7378 mL/g, BothA 𝜐̅ =0.7316 mL/g, BothB 𝜐̅ =0.7327 mL/g, BothC 𝜐̅ =
0.7364 mL/g, ρ = 1.0004 g/mL and η = 1.009 cP. All samples were centrifuged at
45,000 rpm, 4°C and sedimentation was monitored by A280 every 10 min for 30
scans. The data were analyzed by Sedfit, using a continuous c(s) distribution
model.
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The final graph, Figure 25C, shows the results of the potential influence of
pure HT on the sedimentation of HT-NR. The two peaks in the combined sample
were not well resolved in the analysis and the apparent shift in the slower
sedimenting species, Sobs=1.195 S, may be influenced by the overlapping peaks.
The peaks at Sobs=2.035 S and Sobs=2.093 S are likely both HT-NR monomers,
the latter shifted due to the overlapping peaks or analysis variation.
In all HT-NR experiments, a faster sedimenting species corresponding to
an HT-NR homodimer was observed.

3.5 In vivo Colocalization
HEK293T cells were cotransfected with fluorescently labelled NR and G,
then visualized with confocal microscopy to observe colocalization by these
polypeptides in vivo. The cells expressed either GFP-NR/mCherry-G or mCherryNR/GFP-G; colocalization is indicated by yellow fluorescence due to overlapping
GFP (green) and mCherry (red). Figure 26 shows that in both combinations, there
was colocalization of the two fragments of TDP-43 indicated by yellow
fluorescence in the merged image. It was also interesting to note that the NR
fragment contains both the NLS and NES but both fragments appeared to localize
to the nucleus.

This is demonstrated by the overlap of the blue Hoechst

fluorescence with the red and green from the expressed polypeptides.
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Figure 26. Confocal microscopy of fluorescently labelled TDP-43 domains in
HEK293T cells. The top row shows cells cotransfected with mCherry-G/GFP-NR
and Hoechst stained.

The bottom row shows cells cotransfected with GFP-

G/mCherry-NR and Hoechst stained.

Both show colocalization of the two

fragments of TDP-43. The TDP-43 fragments also appeared to localize to the
nucleus as indicated by the overlap with the blue fluorescence. The images were
taken at 600x magnification.
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Chapter 4: Discussion, Conclusion and Future Direction

4.1 Detecting TDP-43 Domain Interactions
Two biophysical techniques, Far Western blotting and AUC, were used to
investigate the existence of an interaction between the C-terminal domain and
either the N-terminal domain or the RNA-binding domain of TDP-43. Recombinant
TDP-43 constructs containing various combinations of the three domains of TDP43 were used in these techniques and analyzed for intermolecular interactions.
TDP-43 is a highly aggregation prone protein and it was difficult to isolate because
it aggregated in inclusion bodies after overexpression in E. coli. The recombinant
polypeptides included a His6-thioredoxin (HT) tag that was utilized in affinity
purification and in solubility. E. coli thioredoxin is a well-studied molecule that
increases solubility of proteins that are prone to form inclusion bodies, such as
TDP-43 (104). For this reason, the polypeptides were not cleaved from the HTtag for this work.
In a Far Western blot, the blotted polypeptides were probed with a
radioactively labelled protein probe that was a suspected binding partner. This
technique requires a strong binding interaction that is detectable at very low probe
concentrations compared to the blotted polypeptides during incubation and
physical separation after significant washing to dissociate non-specific binding and
excess radiation. This is in contrast to AUC, where the two polypeptides were
present in much higher concentrations and the faster sedimenting polypeptide is
always in contact with its potential binding partner, maximizing the effects of an
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interaction on the rate of sedimentation. This situation is demonstrated in Figure
27. For this reason, much weaker interactions are detectable by AUC that may
have presented as negative in a Far Western blot.

These two techniques

complemented each other to establish both strength and minimal residue
requirements of the domains of TDP-43 for interaction.
4.1.1 The effects of buffers in AUC—The influence of various salts on protein
stability in solution has been well studied and those that more closely mimic
physiological levels are ideal for studying native interactions (105). TDP-43 is an
aggregation-prone protein and many of the typical buffers for AUC, particularly
high salt buffers, were not suitable for studying interactions because they caused
rapid precipitation of HT-G. Some work was done to introduce low levels of NaCl
into the buffer but HT-G rapidly precipitated and was not usable (data not shown).
Instead, the purified domains were typically solubilized in buffers with components
that prevent protein interactions/aggregation including ArgHCl (not used in AUC)
and TFA, with low levels of Tris base and tricine. TFA is a known additive for
dissolving and solubilizing aggregation prone proteins, including β-amyloid (103).
Adding TFA was useful for the initial AUC interactions studies with HT-G and there
appeared to be some shift in the sedimentation of HT-NR.

However, the

mechanism by which TFA solubilizes proteins is not well understood and it was not
determined if TFA was removed with dialysis. Therefore, it was of interest to find
different conditions to further investigate binding to eliminate any possibility of TFA
affecting interactions. The solubility of HT-G in low levels of Tris-HCl, Tris base
and tricine was critical to the interaction studies.
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Figure 27. Schematic representation of the sedimentation of two species, with and
without interaction. The black figures represent the centrepiece where the sample
is loaded for analysis. White space is buffer. Blue is the faster sedimenting
species that over time, sediments to the back of the centrepiece. Yellow is the
slower species that sediments at a slower rate compared to blue.

Green

represents the space where both species are sedimenting. In a non-interacting
system, the two species sediment at the same rates as observed individually. In
an interacting system, the blue species sediments at a faster rate than when alone
because it is always in the presence of yellow (shown in green). Yellow sediments
at the same rate because it has lost contact with blue.
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By dialyzing HT-G directly into a buffer with 25 mM Tris base and 50 mM tricine,
the effects of bound TFA were eliminated and more reliable results achieved from
the SV studies.

4.1.2 The RNA-binding and C-terminal domains interact in Far Western blots—To
investigate the ability of TDP-43 domains to interact, Far Western blots were used
to visualize domain interactions by probing immobilized TDP-43 with purified

125I-

HT-NR or 125I-HT-N (Figure 17). Strong interactions were observed between

125I-

HT-NR and HT-NRG, HT-RG, HT-R and HT-G while

125I-HT-NR/HT-NR

had a

weak signal. No interaction was observed between 125I-HT-NR and HT-N. These
results suggested that the RNA-binding domain and C-terminal domain likely
contained the major sites of interaction. Therefore, it is possible that in the intact
protein the intrinsically disordered C-terminal domain folds back to interact with
RNA-binding domain to modulate some function of TDP-43 similar to that in other
IDPRs (92, 93). In TDP-43, this could involve RNA-binding or cellular localization
by blocking the NES. The C-terminal domain has been observed to bind other
proteins (33, 42). These interactions may relieve intramolecular inhibition by the
C-terminal domain or may be blocked by the interaction. In either case, cellular
functions of TDP-43 would be modulated by a C-terminal/RNA-binding domain
interaction.
The weaker interactions with

125I-HT-NR/HT-NR

and

125I-HT-N

with any of

the blotted TDP-43 constructs suggest that TDP-43 may participate in additional
interactions but these may only assist the stronger, RNA-binding/C-terminal
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domain interaction or may require additional molecules such as RNA or proteins.
Dimerization by the N-terminal domain has been observed through crosslinking
techniques (48) and it is possible that Far Western blotting is not a sufficient
technique for detecting this interaction.
One common ALS mutation in the C-terminal domain, Met337Val, was also
tested for interaction with

125I-HT-NR

(Figure 18). The level of interaction was

similar to that of the wildtype HT-G. It would be interesting in further work to
compare this with other ALS mutations to see if there is a different result for the
other known mutations. It is not clear what the impact of the various mutations is
on the fate of TDP-43 but comparing the interaction abilities of the mutants may
provide some information.

4.1.3 The extreme C-terminus is critical for interactions—In addition to binding with
nucleotides or proteins, inhibition by IDPRs may also be relieved through posttranslational modifications such as phosphorylation (92, 93). With some confirmed
sites of phosphorylation within the C-terminal domain at Ser409/Ser410 (79),
mutants of HT-G were created that contained phosphomimetic residues to observe
the effects on the interactions detected by Far Western blotting (Figure 18). In all
three phosphomimetic constructs, binding with

125I-HT-NR

was reduced. Of the

single phosphomimetics, HT-G-S409D showed a greater reduction in binding with
125I-HT-NR

than HT-G-S410D. HT-G-S409D also had similar reduction to that of

the double phosphomimetic. A virtually complete reduction was observed in the
deletion construct where residues 407-416 were deleted. These results together
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indicate that the extreme C-terminus of TDP-43 is important for the binding
observed between the C-terminal domain and HT-NR. Addition of a negative
charge by the phosphate group to this region may interrupt the binding interface
through steric hindrance or electrostatic repulsion.

4.1.4 HT-NR and HT-G interaction increases sedimentation in solution—The
interpretation of the data collected from the sedimentation velocity experiments
was not entirely clear but some general trends were evident that do support the
presence of an interaction.

Intramolecular interactions, such as the one

hypothesized in this work, are likely weak in binding energy but are strengthened
by proximity when both regions are within the same polypeptide (92).

By

separating the interacting domains, the weaker interaction was more likely to be
observed through a shift in the sedimentation boundary of monomers rather than
a single heterodimer boundary. In theory, the effect on sedimentation would be
observable because the 45-kDa HT-NR polypeptide was both larger and less
extended than the disordered, 30-kDa HT-G polypeptide and the HT-NR would
therefore sediment more rapidly than HT-G.

If weak interactions occur, the

heterodimer would sediment faster, shifting the apparent sedimentation of HT-NR
to a larger Sobs. HT-NR passing through a “sea” of HT-G would also increase that
chances of multiple binding and release events, making the overall evidence of
interaction more apparent.

The sedimentation of HT-G would not be as

significantly influenced because that boundary would be separated from HT-NR
during the experiment. (106)
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The shifts in the Sobs for the peaks in the first three SV experiments (Figure
24) are summarized in Table 3. In each experiment, the boundary assigned to HTNR sedimented more rapidly in the combined sample than the HT-NR alone. The
shift also increased as the buffer conditions became more favourable for protein
interactions.

This result is as expected from the above explanation of

sedimentation and interactions with HT-G and both the monomeric and
heterodimeric forms of HT-NR were observed.

4.1.5 The extreme C-terminus is not sufficient for interactions—The results
discussed in the previous section supported an interaction by the C-terminal
domain and implied that the extreme C-terminus was critical for the interaction. All
of the Far Western studies between HT-NR and wild-type HT-G showed a positive
interaction. When modifications were made to the extreme C-terminal region of
HT-G through phosphomimetics or deletion, the interaction was reduced or nearly
abolished. The next step was to determine if this region was sufficient for the
interaction.
To further investigate the binding region of the C-terminal domain, mutants
were constructed that deleted residues 262-385, leaving the extreme C-terminus
attached to HT for interaction studies. There was no observable interaction in the
Far Western blots with either of the tested polypeptides (Figure 19). This could be
due to two situations: either how these proteins bound to the Immobilon membrane
or else that more of the C-terminal domain contributes to binding. In the first
situation, accessibility of the probe to the blotted protein domain is dependent on
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Observed Sedimentation Coefficient (Sobs) Shift

Buffer Condition

HT-NR → Combined
(Difference)
2.174 S → 2.267 S
Peak 1
(0.0930 S)

HT-G → Combined
(Difference)

1.583 S → 1.603 S
(0.020 S)

Tris25TFA0.1TCEP1
Peak 2

3.472 S → 3.560 S
(0.088 S)

Peak 1

2.366 S → 3.192 S
(0.826 S)

Tris25Tris25TCEP1
Peak 2

1.711 S → 1.789 S
(0.078 S)

3.754 S → 4.377 S
(0.623 S)
2.124 S → 3.351 S

Tris25Tris50TCEP1

1.555 S → 1.697 S
(0.142 S)

Peak 1
(1.227 S)

Table 3. Observed sedimentation coefficient shifts in SV experiments with HT-NR
and HT-G.

Three different buffer conditions were used to study the same

interaction. Shown are the Sobs for the individual samples shifted (→) to the
corresponding peak in the mixed sample. The difference is provided in brackets.
Peak 1 refers to the monomeric HT-NR boundary.

Peak 2 is the potentially

homodimeric HT-NR boundary, if resolved by the analysis.
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the orientation of the transferred protein on the Immobilon membrane and whether
the binding site is accessible to the probe in solution. In these small constructs,
the binding region is so close to the His6-thioredoxin tag, there is a chance that the
remaining residues of the C-terminal domain were inaccessible to the probe and
therefore no binding could occur. In the second case, there may be necessary
residues for binding elsewhere in the C-terminal domain that were removed with
both deletion mutants (HT-G-Δ407 and HT-G386-416) and deletion of either reduced
the binding energy such that it was too low for the Far Western blot technique.
Since the C-terminal domain is disordered, it is possible to have multiple sites of
contact spread through the domain that individually have low binding energies but
collectively create a strong interaction. Through studying the binding kinetics of
IDPRs, many of these domains adapt an induced fit structure that depends on an
initial binding step that triggers a conformational change for full binding (reviewed
in 107). The final bound state would involve multiple sites through the domain and
therefore weak binding may be detectable with many regions of the domain.
In the second set of SV experiments (Figure 25), a series of truncations
were used to try to elucidate a more defined region of binding by the C-terminal
domain. Even though there was no detection of an interaction in the Far Western
blot experiments with the HT-G386-416 construct, SV would present a more
favourable environment for binding because the technique is more sensitive to
weak binding due to the higher concentrations employed. Table 4 summarizes the
Sobs shifts for these experiments. As anticipated, the shift in HT-NR sedimentation
observed in the presence of HT-G386-416 was greater than that with HT-G386-406 or

93
HT. This agrees with our prediction that there are residues within the extreme Cterminus of TDP-43 that form an interaction with the RNA-binding domain.
HT-G386-406 was expected to have no interaction with HT-NR based on the
observation in the Far Western blot experiments with HT-G-Δ407. However, the
same sensitivity argument mentioned above for using SV applies here.

The

residues in HT-G-Δ407 may not have had high enough binding energy to be
detectable by a Far Western blot but the few remaining residues within HT-G386-406
had a strong enough binding to increase the sedimentation of HT-NR detected by
SV. Overall, the extreme C-terminus of TDP-43 is critical to the interaction with
HT-NR but it is not sufficient for high affinity binding. The results suggested some
binding energy is provided by other residues within the C-terminal domain.
Finally, there was very little change in the sedimentation of HT-NR in the
presence of the purified HT tag alone. This confirmed that it is the presence of the
C-terminal domain of TDP-43 that binds HT-NR and not the tag.

4.1.6 Variation in Sobs due to Sedfit analysis and user error—As alluded to
previously, the apparent shift in the HT boundary when in the presence of HT-NR
may be attributed to the poor resolution of the two peaks during analysis. There
is also clear variation in the Sobs for identical polypeptides run in different
experiments. The software used for this analysis, Sedfit, required significant user
input through placement of limits and boundaries during the analysis.

For

example, if there is poor data collection due to a small leak during centrifugation,
there may be fewer usable data points in one cell compared to another.
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Observed Sedimentation Coefficient (Sobs) Shift
HT-NR → Combined
(Difference)
Peak 1

2.182 S → 2.695 S
(0.513 S)

Peak 2

3.718 S → 3.792 S
(0.074 S)

Peak 1

2.079 S → 2.412 S
(0.333 S)

Peak 2

3.418 S → 3.631 S
(0.213 S)

Peak 1

2.035 S → 2.093 S
(0.058 S)

Peak 2

3.601 S → 3.704 S
(0.103 S)

HT-G386-416

HT-G386-406

HT

Other → Combined
(Difference)
1.065 S → 1.392 S
(0.327 S)

1.121 S → 1.241 S
(0.120 S)

0.987 S → 1.195 S
(0.208 S)

Table 4. Observed sedimentation coefficient shifts in SV experiments with HT-NR
and HT-G386-416, HT-G386-406 and HT. Shown are the Sobs for the individual samples
shifted (→) to the corresponding peak in the mixed sample. The difference is
provided in brackets. Peak 1 refers to the monomeric HT-NR boundary. Peak 2
is the potentially homodimeric boundary.
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This results in a smaller radial range of analyzable points, which has some impact
on the observed sedimentation coefficients reported. The radial range of data
analyzed within an experiment (three SV data sets) was kept relatively constant
but between experiments, the range was not as closely monitored. This explains
the variability in Sobs for HT-NR across the experiments but does not negate the
larger shifts due to interaction. Other sources of variability include cell alignment,
window imperfections and temperature variability, to name a few. In a study on
the impact of such variables, Arthur et al. (2008) found that Sobs was not
significantly affected by these variables (108). Therefore, the above conclusions
based on gross changes in sedimentation are more likely due to real interactions
and not simply artifacts or experimental error.

4.2 Implications for intramolecular interactions in TDP-43 function
The functions of TDP-43 within a cell involve RNA-binding, protein-protein
interactions and transport between the nucleus and cytoplasm (19).

These

functions of TDP-43 must be tightly regulated by the cell to ensure that miRNA is
correctly processed, or mRNA is spliced, transported or even degraded. The
presence of an IDPR within TDP-43, the C-terminal domain, suggests the
possibility of this domain as a regulatory module that forms an intramolecular
interaction to moderate TDP-43, for example, binding with RNA, binding with other
proteins or even cellular localization.
The most obvious role of the C-terminal domain would be in regulating or
responding to RNA binding. If the binding interface for the C-terminal domain
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covers the RNA-binding surface, this intramolecular interaction could act by
inhibiting RNA binding.

Relieving inhibition could involve post-translational

modifications to the C-terminal domain or proximity to an intermolecular binding
partner of TDP-43. Alternatively, proximity to an ideal binding sequence within an
RNA molecule could dissociate the C-terminal domain, making it available for
protein interactions.
Similar to that of RNA-binding, an intramolecular interaction by the Cterminal domain could moderate access to the binding region for interactions with
other protein binding partners of TDP-43 within a cell. As discussed in Section
1.2.4, the C-terminal domain participates in a number of protein-protein
interactions and through an intramolecular interaction involving the C-terminal
domain, these interactions could be inhibited.

Upon release, again by RNA-

binding or post-translational modification, the region for binding would be exposed
to nearby proteins. The C-terminal domain could then bind with the appropriate
proteins for its current role, perhaps to be transported out of the nucleus. Upon
release of the protein partner after TDP-43 has completed its role, the C-terminal
domain could rebind intramolecularly and once more shield interactions.
TDP-43 contains both a NLS and a NES (31). The C-terminal domain could
act as a regulator of access to the NLS or NES. The NES is located within the
RNA-binding domain (residues 239-250). The experiments in this work have
suggested that the C-terminal domain forms an interaction with the RNA-binding
domain. In the bound state, the C-terminal domain may prevent recognition of the
NES by transport machinery. Masking of localization signals has been observed
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in many other proteins (reviewed in 109). Upon release of the C-terminal domain
interaction by RNA-binding or post-translational modification, for example, the
NES would be exposed and export of TDP-43 could occur. TDP-43 would then be
returned to the nucleus after rebinding of the C-terminal domain and subsequent
masking of the NES. TDP-43 aggregates are found localized to the cytoplasm of
ALS-affected neurons and it is the C-terminal domain that is implicated in
nucleating aggregation (1, 3, 31, 64, 110). Loss of intramolecular binding by the
C-terminal domain, possibly through excessive interactions leading to aggregation,
may strand TDP-43 in the cytoplasm. The in vivo confocal microscopy studies
demonstrated that GFP-NR and mCherry-G expression were colocalized to the
nucleus in HEK293T cells while little (if any) expression was seen in the cytosol.
Considering the above discussion about the impact of the NES, there is also the
consideration of the NLS, located within the N-terminal domain at residues 82-98.
The structure formed by the N-terminal domain is just starting to be studied and it
is possible that masking of the NLS also occurs within this domain. At this time,
the relative strength between the two signals is not known, but it would be
interesting to study further.

4.3 Implications for intramolecular interactions in TDP-43
dependent pathogenesis
4.3.1 ΔNH increased the interaction—The 416 amino acid isoform of TDP-43 used
throughout this study was isolated from neuropathologically normal human brain
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(18) but there is a 414 amino acid isoform that is more commonly cited in the
literature. The 414 amino acid isoform was originally isolated from HeLa cells (7)
and is also detectable in HEK293T cells (18). The longer isoform has two amino
acid residues added at the C-terminus and its presence in the nervous system has
interesting implications on the importance of the extreme C-terminus in TDP-43
regulation. While the expression of this isoform was not determined throughout
human tissues, it would be interesting to determine if this isoform is neuronal tissue
specific. Deleting the last two residues of the 416 amino acid HT-G, making the
HT-G-ΔNH C-terminal domain, appeared to increase binding with

125I-HT-NR

about two-fold. If intramolecular binding by TDP-43 is critical to stability and
aggregation prevention, expression of the longer isoform in only certain tissues
would explain the more aggregation-prone state of TDP-43. The shorter isoform
may form a more stable intramolecular interaction and therefore be less
susceptible to the triggers for aggregation. TDP-43 is a ubiquitously expressed
protein, present in many different tissues (8), but its aggregation has thus far
largely been observed in the nervous system. There is some evidence for TDP43 involvement in inclusion body myopathy, a disease of the muscle, but the
isoform of TDP-43 present in muscle was not determined (111). Exploring this
interaction further will be interesting for understanding the susceptibility of neurons
to aggregation of TDP-43 and if it is related to the weaker binding isoform that is
expressed.
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4.3.2 Phosphorylation of C-terminal serines in TDP-43—As discussed in Chapter
1, the aggregates found in neurons often contain TDP-43 phosphorylated at
Ser409/Ser410 (82) and it is unclear whether phosphorylation or aggregation
occurs first. Considering the current results, arguments for both exist (Figure 28).
If aberrant phosphorylation of the C-terminal domain occurred, a potentially critical
step in moderating TDP-43 function would be disrupted, thus allowing for
excessive interactions to occur and aggregate formation.

Alternatively, if

aggregates of TDP-43 form, phosphorylation and cleavage may be preventative
steps by a cell to reduce further aggregation with full length TDP-43 from occurring.
In either case, disruption of this interaction could have an impact on the fate of
TDP-43 in a neuron. There has been little exploration into any in vivo pathways
for dephosphorylation of TDP-43.

4.4 Conclusion and Future Directions
My hypothesis was that the C-terminal domain of TDP-43 is involved in
intra- or intermolecular interactions. The experimental results presented in this
work support my hypothesis and demonstrate that the C-terminal domain is
capable of interaction with the RNA-binding domain of TDP-43. Disruption of the
interaction

due

to

phosphomimetic

mutations,

similar

to

pathological

phosphorylation, was also demonstrated. I further hypothesize that this interaction
could be critical to TDP-43 function within a cell and disruption is one critical step
in disease pathogenesis. Future work should be focused both in vitro and in vivo
to further investigate the functional implications of an intramolecular interaction.
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Figure 28.

Schematic diagram illustrating two possible functions of

phosphorylation in aggregation.

On the left side, TDP-43 is aberrantly

phosphorylated in the disease state which leads to aggregate formation. On the
right side, there is some trigger that causes TDP-43 to aggregate and
phosphorylation of TDP-43 is a mechanism to prevent further aggregation.
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One important in vitro step should be purification of the full length TDP-43
protein with greater yields. This will provide an important piece of information for
comparison with the current results. More precise mapping of the binding interface
within the RNA-binding domain would be important. This could be achieved by
introducing a crosslinking system where a photo-crosslinkable agent would be
added in the C-terminal domain and upon binding and activation of crosslinking,
the C-terminal domain would be chemically bound at the interface. Then trypsin
digestion and a peptide identification technique such as mass spectrometry could
follow to identify the bound region in the RNA-binding domain. Once a more
precise region of interaction is known for both domains, site directed mutagenesis
could be used to mutate certain residues that might be critical for an interaction
and then perform the same interaction studies to determine the impact of the
mutations.
Investigation of the impact of oligonucleotides on the interaction would
provide important information of what functions of TDP-43 might be regulated.
Using a technique such as an electrophoretic mobility shift assay, a radio-labelled
oligonucleotide could be added with the HT-NR and HT-G to observe how the
movement of HT-NR and HT-G are altered by the presence of RNA. The same
techniques described in this work and future work should also be used to identify
any differences in C-terminal domain binding due to other known mutations in
disease. This would complement purification of the mutant C-terminal domains
and analysis by AUC. Co-immunoprecipitation could also be used to detect an
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interaction between co-expressed TDP-43 polypeptides from a eukaryotic cell
lysate.
For in vivo work, more colocalization studies would be important for
deciphering the biological relevance of the interaction. This could be achieved
through studies with lower construct expression and through introducing some of
the other mutations or truncations used in this work. Performing an RNA stability
assay, such as a luciferase assay, would provide a more direct functional
relevance of an interaction through observing the difference between full-length
TDP-43 and the co-expression of NR and G polypeptides.
Overall, the work presented here is the initial step to defining an
intramolecular interaction in TDP-43. This is important to the field because it
provides insight into the possible mechanisms of TDP-43 that may be altered in
disease. An interaction such as this has significant implications on how TDP-43
should be studied both in the RNA-binding and neurodegenerative disease fields.
The presence of the C-terminal domain in studies is variable depending on the
desired results of the work, whether it be observing aggregation with an excess of
this domain or determining structural behavior with the C-terminal domain cleaved.
This type of interaction is critical to the normal behaviour of TDP-43 and therefore
the C-terminal domain should not be cleaved for ease of purification or minimizing
in vivo aggregation to properly study the natural behaviour of TDP-43. Since TDP43 is a highly conserved protein, all domains are important to its function. Through
interdomain interactions, its variable roles within a cell could be much more tightly
regulated and integral to cell survival than initially presumed. Further efforts to
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establish the molecular and biological basis for this interaction should provide
better insight into the role of TDP-43 in normal cellular homeostasis and in disease
pathogenesis.
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